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Sentence summary: The review summarises the state of the art for studying gut microbes-4 
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ABSTRACT 33 
A close symbiotic relationship exists between the intestinal microbiota and its host. A 34 
critical component of gut homeostasis is the presence of a mucus layer covering the 35 
gastrointestinal tract. Mucus is a viscoelastic gel at the interface between the luminal content 36 
and the host tissue that provides a habitat to the gut microbiota and protects the intestinal 37 
epithelium. The review starts by setting up the biological context underpinning the need for 38 
experimental models to study gut bacteria-mucus interactions in the digestive environment. 39 
We provide an overview of the structure and function of intestinal mucus and mucins, their 40 
interactions with intestinal bacteria (including commensal, probiotics and pathogenic 41 
microorganisms) and their role in modulating health and disease states. We then describe the 42 
characteristics and potentials of experimental models currently available to study the 43 
mechanisms underpinning the interaction of mucus with gut microbes, including in vitro, ex 44 
vivo and in vivo models. We then discuss the limitations and challenges facing this field of 45 
research. 46 
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INTRODUCTION 51 
The human gastrointestinal (GI) tract harbours a complex and diverse community of 52 
microbes, including 10 trillion of microorganisms, collectively referred to as the gut 53 
microbiota (Sender et al., 2016). Several regulatory mechanisms cooperate to maintain 54 
intestinal homeostasis and a disturbance of the relationship between the gut microbiota and 55 
the host can results in several disorders including chronic inflammatory diseases and 56 
metabolic syndromes (Rooks & Garrett, 2016). While the intestinal microbiota provides 57 
important benefits to the host, such as calorie extraction and immune system maturation, it 58 
also holds the power to activate various innate and adaptive immune signalling which can 59 
lead to uncontrolled and deleterious intestinal inflammation (Pickard et al., 2017). A key 60 
component in maintaining a beneficial relationship between the commensal microbes 61 
inhabiting the intestine and the host is the presence of an appropriate barrier that prevents 62 
bacteria to reach and persist on the epithelial surface (Johansson & Hansson, 2016, Sicard et 63 
al., 2017, Bretin et al., 2018). It is well acknowledged that intestinal epithelial cells (IECs) 64 
provide a physical and biochemical barrier that prevents the translocation of commensal 65 
bacteria to the underlying host tissue. In addition, there is an emerging paradigm that the 66 
mucus layer is an important modulator of human health in mediating the homeostatic 67 
relationship between the gut microbiota and the host. On the luminal side, the mucus layer 68 
provides the first physical, chemical, and biological line of defence against large particles, 69 
including commensal bacteria and invading pathogens, segregating them from IECs (Turner, 70 
2009, Peterson & Artis, 2014). Furthermore, mucus provides a biological niche for a 71 
microbial community, referred to as mucus-associated microbiota, which is likely to have a 72 
major influence on human health (Martens et al., 2018). However, advances in this field of 73 
research have been hampered by the lack of suitable model systems recapitulating all the 74 
interactions occurring at the mucosal interface. This review provides an overview of currently 75 
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available experimental models to study the interplay between gut bacteria and intestinal 76 
mucus at a mechanistic level, and summarizes their main applications and the challenges 77 
remaining in this field of research.  78 
79 
 6 
1. Overview of mucus structure and function in the gastrointestinal (GI) tract  80 
 81 
1.1. Mucus structural organisation 82 
 83 
Mucus structure. Mucus is a highly hydrated gel made up of more than 98% water that 84 
makes it totally transparent, microscopically invisible and difficult to study. This aqueous 85 
viscoelastic secretion also contains electrolytes, lipids and various proteins (Bansil & Turner, 86 
2018). Mucus is found throughout the entire GI tract from the stomach to the large intestine, 87 
with its thickness and structure varying depending on the location, reflecting its various 88 
protective functions.  89 
The mucus in the small intestine consists of one layer, while the stomach and colon 90 
have a bi-layered mucus. In human stomach, the mucus is about 200–400 μm in thickness and 91 
consists of an inner layer loosely attached to the epithelial surface, keeping the surface neutral 92 
(pH 7) while the gastric lumen pH is acidic (pH 2), and an outer layer which is mobile on the 93 
luminal side. Only few bacteria have evolved strategies to colonise the stomach, among which 94 
Helicobacter pylori is a specialist (Atuma et al., 2001, Juge, 2012). In the small intestine, 95 
mucus fills up the space between the villi but is not attached to the epithelium and is 96 
somewhat permeable to bacteria (Atuma et al., 2001). In the colon, the two layers mediate 97 
opposite interactions with the microbiota; whereas the outer layer (up to 800 μm) is densely 98 
colonised by an important microbial biomass, the inner layer (>β00 μm in humans) is virtually 99 
devoid of bacteria leaving a space virtually free of microbes (commensals and or pathogens) 100 
leaving a space virtually free of microbes above the epithelium (Johansson et al., 2013). 101 
However, single-cell imaging at tissue scale in mice revealed the presence of bacteria in close 102 
proximity of the epithelium (Earle et al., 2015). Among commensal microorganisms, 103 
Segmented Filamentous Bacteria (SFB) are immunomodulatory commensals with the ability 104 
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to adhere to IECs and to invade this mucus layer without invading the host (Hedblom et al., 105 
2018, Ladinsky et al., 2019). Of note, a recent study revealed differences in mucus 106 
organization between the proximal and distal colon of rodents (Kamphuis et al., 2017): in the 107 
later, the mucus layer is attached to the faecal pellet and absent from the surface of the 108 
epithelium (Kamphuis et al., 2017).  109 
Other studies demonstrated that the mucus thickens as the microbiota become more 110 
diverse, as particularly evident in the colon (Jakobsson et al., 2015). This is also supported by 111 
studies using germ free mice showing an impairment in mucus structure (Johansson et al., 112 
2008, Johansson et al., 2013, Jakobsson et al., 2015). Gnotobiotic mice colonized with human 113 
faecal microbiota present a mucus layer structure resembling that of conventional mice by day 114 
7 post-colonization (Hayes et al., 2018). Animals housed in distinct rooms of the same animal 115 
facility exhibit distinct microbiota profiles that are associated with large differences in the 116 
inner colon mucus layer, thereby affecting mucus barrier properties (Jakobsson et al., 2015). 117 
Also, it has been demonstrated in mice that mucus becomes thinner with age (Elderman et al., 118 
2017). Variations in the mucus thickness and spatial organisation of the gut microbiota in 119 
mice were also found to be dependent of the diet (Earle et al., 2015). Interestingly, the 120 
thickness of the mucus layer has been shown to undergo circadian fluctuations, with highest 121 
microbial proximity to the mucosal surface during the dark phase (Thaiss et al., 2016). 122 
 123 
Mucus secretion. The mucus is produced and secreted by specialized cells namely goblet 124 
cells located in the crypt in the small intestine and in higher numbers in the upper crypt in the 125 
colon (Johansson & Hansson, 2013, Johansson & Hansson, 2016, Sicard et al., 2017). Before 126 
secretion in the gut lumen, mucin polymers are stored in mucin granulae within the goblet 127 
cells (Johansson et al., 2011, Johansson et al., 2013). The function of goblet cells varies 128 
depending on their localisation in the small intestinal or colonic crypts (Pelaseyed et al., 129 
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2014). Apart from their role in secreting mucus, small intestinal goblet cells can play a role in 130 
delivering luminal material to the immune system (Pelaseyed et al., 2014). Interestingly, a 131 
study from Gunnar Hanson’s laboratory identified a subpopulation of goblet cells called 132 
“sentinels” goblet cells (Birchenough et al., 2016). These cells are able to sense Toll-like 133 
receptor (TLR) microbial ligands at the entrance of colonic crypts and trigger the activation of 134 
NLRP6 inflammasome, leading to mucus secretion from neighbouring goblet cells to defend 135 
the colon against bacterial invasion (Birchenough et al., 2016).  136 
Renewal of the mucus is an important factor to preserve epithelial damage and 137 
bacterial exposure. The colonic mucus has a rapid turnover, since the inner mucus layer is 138 
renewed within 1 hour (Johansson, 2012), while the gut epithelium renewal takes around 4-5 139 
days (De Weirdt & Van de Wiele, 2015).  140 
 141 
Gastro-intestinal mucins. The main structural components of mucus are large glycoproteins 142 
called mucins. The protein sequences of mucin domains share a common core structure rich 143 
in the amino acids prolin (P), threonine (T) and serine (S) called the PTS domain. These 144 
domains are then decorated by O-linked glycans made up of N acetylgalactosamine 145 
(GalNAc), N-acetylglucosamine (GlcNAc), galactose (Gal) and usually terminated by sialic 146 
acid and fucose (Juge, 2012, Johansson & Hansson, 2016, Sicard et al., 2017). These O-147 
glycans render the mucin domains highly resistant to protease degradation and confer mucins 148 
their high-water binding capacity.  149 
Mucins are produced as transmembrane mucins or secreted gel forming mucins (Juge, 150 
2012, Johansson et al., 2013). In the stomach, MUC1 and MUC5AC are produced by the 151 
superficial epithelium, while MUC6 are secreted by the stomach glands (Johansson et al., 152 
2013, Johansson & Hansson, 2016). In the small intestine and colon, mucus is structurally 153 
built around the mucin-2 glycoprotein (MUC2). The folding and dimerization of MUC2 is a 154 
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demanding process owing to the large number of disulfide bonds, and a defect during this 155 
process may affect the structure and function of intestinal mucus (Johansson et al., 2011). 156 
Proteolytic cleavages of MUC2 catalysed by the host as well as bacteria enzymes favour the 157 
transition from firm to loose layer form and allow bacteria to penetrate into the mucin net-like 158 
structure of the outer mucus layer (Johansson et al., 2008). In addition to this proteolytic 159 
activity, the degradation of mucin glycan chains by bacterial glycosidases contribute to the 160 
establishment of a microbial community in the outer mucus layer (Johansson et al., 2008, 161 
Pelaseyed et al., 2014).  162 
 163 
Mucin glycosylation. Glycosylation is the most frequent post-translational modification of 164 
proteins and can occur in N-linked and O-linked form, and O-glycosylation is the main 165 
modification of mucins (Arike & Hansson, 2016). Mucin-type O-glycans are built from eight 166 
core structures, with core 1, core 2, core 3 and core 4 glycans most commonly found in 167 
intestinal mucins (Brockhausen et al., 2009). O-glycosylation is initiated in the Golgi 168 
apparatus by the addition of a GalNAc residue to the hydroxyl group of serine and threonine 169 
of the mucin backbone. Further elongation and branching of the O-glycan chains is governed 170 
by a large family of glycosyltransferase enzymes (Bennett et al., 2012). The oligosaccharides 171 
can be further modified by addition of histo-blood group antigens (ABO, Lewis), secretor (H) 172 
epitopes and sialic acids and sulfate (Rossez et al., 2012, Bansil & Turner, 2018). Mucin 173 
glycosylation varies along the GI tract (Robbe et al., 2003, Robbe et al., 2004, Holmen 174 
Larsson et al., 2013) and is linked to microbial colonization (Juge, 2012, Bergstrom & Xia, 175 
2013, Tailford et al., 2015, Arike et al., 2017). Mounting evidence suggests that mucin 176 
glycosylation is critical to the biological and physical role played by mucus in the gut by 177 
influencing the physico-chemical properties and penetrability of mucus and by modulating the 178 
composition of the associated mucus-associated microbiota (see section 1.3). Not 179 
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surprisingly, an alteration of mucin O-glycosylation profile has been reported in intestinal 180 
diseases associated with an impaired gut barrier function such as inflammatory bowel disease 181 
(IBD) and colorectal cancer (Larsson et al., 2011, Theodoratou et al., 2014) as also supported 182 
by work in animal models (Bergstrom et al., 2017) (see also section 4.5). 183 
 184 
1.2. Mucus function in the gut 185 
 186 
For decades, mucus has been considered to act as a simple physical barrier protecting 187 
the host, but mounting evidence suggests that mucus plays additional biological and 188 
immunological roles in maintaining gut homeostasis. The coating gel of mucus is acting, in 189 
concert with the immune system, the intestinal epithelium and the gut microbiota, to provide a 190 
physical, biological, and chemical line of defence against potentially harmful invaders while 191 
harbouring a distinct microbial community having a major influence on host health. 192 
Throughout the gut, the viscous mucus secretion acts as a lubricant that helps the 193 
progress of digestive matter along the GI tract and protects the underlying epithelium from 194 
excessive mechanical or chemical stresses. In the stomach, the mucus coating creates a pH 195 
gradient that protects the epithelium against the crude acidic gastric environment. Mucus acts 196 
as a size exclusion filter for larger compounds while selectively allowing transport of small 197 
molecules such as gases, ions, nutrients, and many proteins to reach the enterocytes (De 198 
Weirdt & Van de Wiele, 2015), but the mucus lining would prevent digestive enzymes from 199 
attacking these cells.  200 
In the colon, the outer mucus layer serves as a biological habitat for various 201 
microorganisms. Indeed, the glycan structures in the mucus provide potential binding sites 202 
and constitute a carbon and energy source to support the growth of commensal but also 203 
pathogenic bacteria (Tailford et al., 2015) (see sections 2.1 and 2.2). It is believed that the 204 
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mucin glycosylation patterns along the GI tract contribute to the microbial tropism of certain 205 
taxa in the mucus (Tailford et al., 2015). 206 
The mucus layer also helps in the protection of the epithelium and, in association with 207 
the immune system, plays a crucial role in intestinal homeostasis. This gel is an important 208 
retention matrix for non-mucin proteins with immune regulatory molecules such as 209 
antimicrobial molecules (e.g. bactericidal RegIIIȖ, α-defensins, secretory immunoglobulins 210 
IgAs, etc), therefore limiting the number of bacteria that can reach the epithelium and the 211 
underlying immune system (Peterson & Artis, 2014, Johansson & Hansson, 2016). This 212 
physical and biological barrier helps to keep the tremendous amount of bacteria that reside in 213 
the lumen as well as enteric pathogens at a safe distance from the epithelium (Chassaing et 214 
al., 2014, Johansson et al., 2014, Chassaing et al., 2015). However, this system can be 215 
subverted and invading pathogens or pathobionts have evolved strategies to circumvent this 216 
barrier by e.g. degrading mucins and/or influencing mucin secretion (Rolhion & Chassaing, 217 
2016). In summary, mucus has a dual role in relation to the gut microbiota, it is an ecological 218 
niche for bacteria by providing adhesion sites and nutrients, while protecting the underlying 219 
epithelium from microbial aggressors that can breach this barrier.  220 
 221 
1.3. The mucus-associated microbiota 222 
 223 
The gut microbiota composition is known to differ along the longitudinal axis of the 224 
GI tract but it also varies transversally from the lumen to the mucosa due differences in key 225 
physiological parameters such as nutrient availability or oxygen gradient. The colonic 226 
epithelium is made of crypts with specific oxygen conditions and various concentrations of 227 
glycans that is a niche for mucin‐ degrading bacteria such as Bacteroides fragilis (Pereira & 228 
Berry, 2017). The use of Carnoy fixative to preserve the mucus layer has been a crucial step 229 
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for the detection of bacteria in the mucosal environment (Johansson et al., 2008). It is now 230 
well appreciated that the faecal microbiota community differs from the luminal, mucosa- or 231 
mucus-associated bacterial communities (Swidsinski et al., 2005, Li et al., 2015) . 232 
Studies in humans demonstrated that the abundance of Bacteroidetes appears to be 233 
higher in faecal/luminal samples than in the mucosa (Eckburg et al., 2005). Members of 234 
Firmicutes phylum and in particular Clostridium cluster XIVa are significantly enriched in the 235 
mucus layer compared to the lumen (Van den Abbeele et al., 2013). Analysis of human 236 
colonic biopsies have also shown a distinct mucosal community enriched in Actinobacteria 237 
and Proteobacteria compared to the luminal community (Albenberg et al., 2014). Certain 238 
species such as Bacteroides acidifaciens, B. fragilis, and Akkermansia muciniphila are 239 
enriched in the outer layer of colon mucus (Derrien et al., 2004, Donaldson et al., 2016).  240 
Similar findings have been observed in animals. Indeed, mice studies have shown that 241 
Firmicutes were enriched in the mucosa-associated microbiota, especially members of the 242 
Lachnospiraceae and Ruminococcaceae families (Tailford et al., 2015). Bacterial species such 243 
as Bacteroides thetaiotaomicron or Escherichia coli display specific genomic repertoires to 244 
persist in the outer mucus layer compared with the same species in the intestinal lumen (Li et 245 
al., 2015). This spatial localisation may be reflective of the radial oxygen gradient that shapes 246 
the mucus-associated and faecal microbiota, since oxygen can favour or impede certain 247 
microorganisms (Albenberg et al., 2014). Moreover, laser capture microdissection (LCM) in 248 
combination with metagenomics studies provided new insights into the composition of the 249 
mucus-associated microbiota (Wang et al., 2010). The use of LCM in mouse models revealed 250 
that this microbial community is especially dominated by Acinetobacter in the colonic crypts 251 
(Pedron et al., 2012). Using LCM coupled to DNA sequencing–based analysis, Chassaing and 252 
Gewirtz recently reported profound differences at the phyla level between the inner mucus 253 
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communities comprising 20%–60% Proteobacteria and a concomitantly marked reduction in 254 
Bacteroidetes as compared to faecal microbiota (Chassaing & Gewirtz, 2019). 255 
Due to a high polysaccharide content (up to 80% of the mucin biomass), mucus 256 
provides an ecological niche for the intestinal microbiota. Mucus-associated bacteria are able 257 
to use oligosaccharides from mucins as binding sites through specific bacterial adhesins that 258 
promote their colonisation (Section 2.1) or as an energy source to support their growth 259 
(Section 2.2). Robbe and colleagues first suggested that the important repertoire of potential 260 
ligands and/or carbon sources in mucins could explain the pattern of bacterial colonisation in 261 
the different gut regions (Robbe et al. 2004). Mucin degradation has been extensively studied 262 
in pathogenic bacteria and more recently investigated in commensal bacteria including A. 263 
muciniphila, Bacteroides spp., Bifidobacteria and Ruminococcus spp. (Derrien et al., 2004, 264 
De Weirdt & Van de Wiele, 2015). A disproportion of bacterial taxa able to invade mucus 265 
could further play a role in the development of the dysbiotic microbiota associated with the 266 
onset of various intestinal diseases (see section 3).  267 
 268 
2. Mucin-bacteria interactions 269 
 270 
2.1. Mechanisms of mucin binding by commensal and pathogenic microorganisms in 271 
the gut 272 
 273 
Cell-surface proteins of pathogens and probiotics/commensal strains have been 274 
implicated in mediating the binding of microbes to intestinal mucus (Fig. 1). These include (i) 275 
specialized cell-surface adhesins or lectins, (ii) appendages such as pili and flagella or (iii) 276 
moonlighting proteins (see (Juge, 2012) for a review). In particular, a considerable amount of 277 
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research has been devoted to the characterization of these adhesins in Lactobacillus species 278 
(as extensively reviewed in (Van Tassell & Miller, 2011, Nishiyama et al., 2016)). 279 
 280 
Mucus binding proteins. Mucus-binding proteins (MUBs) containing a variable number of 281 
Mub repeats are unique to gut inhabiting Lactobacilli and these proteins have been thoroughly 282 
characterised in Lactobacillus reuteri, a gram-positive bacterial species inhabiting the GI tract 283 
widely used as a probiotic (Frese et al., 2011). MUB from L. reuteri ATCC 53608 is one of 284 
the best studied examples of mucus adhesins in commensal bacteria. It is a large protein 285 
consisting of six type 1 repeats (Mub1) and eight type 2 repeats (Mub2) with each repeat 286 
divided into a mucin binding (MucBP) domain and an immunoglobulin binding protein 287 
domain (Kuznetsova, 1990, MacKenzie et al., 2009, Etzold et al., 2014). The Mub repeats 288 
mediate binding to mucin glycans, through interactions with terminal sialic acid (Etzold et al., 289 
2014, Gunning et al., 2016), and Igs (MacKenzie et al., 2009). MUB has the shape of a long, 290 
fibre-like structure, of around 180 nm in length (Etzold et al., 2014), and forms appendices 291 
reminiscent to pili found in pathogenic and, more rarely, other commensal bacterial species. 292 
However, in contrast to pathogenic pili which adhesin is restricted to the N-terminal tip, MUB 293 
interactions with mucin glycans occur through its long and linear multi-repeat structure, as 294 
shown by atomic force spectroscopy (Gunning et al., 2016). This multivalent binding would 295 
restrict penetration through mucus and limit access of the bacteria to the epithelium surface. 296 
In addition, MUB from L. reuteri ATCC 53608 was recently shown to modulate 297 
inflammatory responses in human monocyte-derived dendritic cells via interaction with DC-298 
SIGN (Bene et al., 2017). The presence of mucus adhesins was also shown to mediate the 299 
binding of L. reuteri strains to both HT-29 and mucus-producing LS174T cells. The binding 300 
of L. reuteri to mucus led to a decreased enteropathogenic E. coli (EPEC) adherence to small 301 
intestinal biopsy epithelium (Walsham et al., 2016). Recombinant Mub proteins containing 302 
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Mubs5s6 domains from Lp-1643 protein of L. plantarum Lp9 have been shown to adhere to 303 
human intestinal tissue sections (Singh et al., 2017) and inhibited the adhesion of 304 
enterotoxigenic E. coli (ETEC) to cultured intestinal HT-29 and Caco-2 cell lines, probably 305 
through the recognition of cell-surface mucins (Singh et al., 2018). Together, these findings 306 
show that the nature and function of these adhesins are strain-specific with the potential to 307 
target either the epithelium or the mucus layer and compete with pathogens.  308 
 309 
Flagella. Several microorganisms have evolved strategies, in particular extracellular 310 
appendages such as flagella, pili and fimbriae, to attach to and to penetrate the mucus layer 311 
(Juge, 2012). Pili and flagella are large polymeric proteins that form long surface structures 312 
involved in bacterial adhesion. Flagella are composed of several thousand copies of flagellin 313 
subunits and have been extensively studied in EPEC and enterohemorrhagic E. coli (EHEC) 314 
for their role in virulence and motility, but their role in mucus binding remains unclear. The 315 
adhesive properties of bacterial flagella to mucus were previously reported for Clostridium 316 
difficile where crude flagella, recombinant flagellar FliC and FliD proteins were shown to 317 
bind to murine mucus (Tasteyre et al., 2001). In pathogenic E. coli strains, the H6 and H7 318 
flagella EPEC E2348/69 and EHEC EDL933 and their flagellin monomers were shown to 319 
bind to mucins and to bovine mucus (Erdem et al., 2007). Further studies then showed that 320 
EPEC and EHEC O157:H7 adherence to HT-29 cells is related to mucin-type core 2 O-321 
glycan, facilitating invasion into host cells (Ye et al., 2015, Ye et al., 2015). However, 322 
flagella are involved in the ability of these pathogenic strains to cross the mucus layer, 323 
conferring a selective advantage in penetrating the mucus layers and reaching the epithelial 324 
surface, as demonstrated with Adherent-Invasive E. coli (AIEC) LF82 (Khodzhakuliev & 325 
Ovezova, 1986). It is therefore tempting to speculate that in EPEC and EHEC, the flagella 326 
have a preference for cell-surface mucins rather than secreted mucus, in line with their ability 327 
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to penetrate the mucus layer and attach onto the cell surface before invasion. In the probiotic 328 
E. coli strain Nissle 1917, a direct interaction was observed between isolated flagella from 329 
EcN and porcine MUC2 and human mucus but not murine mucus. The mucus component 330 
gluconate was identified as one receptor for the binding of EcN flagella (Troge et al., 2012). 331 
EcN was therefore proposed to confer the probiotic strain the ability to compete for binding 332 
sites on host tissue with bacterial pathogens. 333 
 334 
Pili. Pili have been identified in Lactobacillus rhamnosus GG where they confer binding to 335 
mucus (Kankainen et al., 2009, von Ossowski et al., 2011) and are predicted to exist in other 336 
Lactobacillus species including L. casei and L. paracasei, based on genomics analyses 337 
(Douillard et al., 2013, Aleksandrzak-Piekarczyk et al., 2015, Nissila et al., 2017). In L. 338 
rhamnosus GG, these are composed of a three-protein complex SpaCBA, which has been 339 
involved in adhesion to mucus, IECs, and immunomodulatory interactions with IEC (Lebeer 340 
et al., 2012, von Ossowski et al., 2013, Ganguli et al., 2015, Vargas Garcia et al., 2015, Bene 341 
et al., 2017). The mucus-binding pili of L. rhamnosus GG shares immunological and 342 
functional similarities with those of the clinical Enterococcus faecium strain E1165. The 343 
binding of E. faecium E1165 to mucus could be prevented by the addition of the mucus-344 
binding SpaC protein or antibodies against L. rhamnosus GG (Tytgat et al., 2016). 345 
Collectively, these studies show the potential of using mucus adhesins from probiotic strains 346 
to prevent the binding of enteric pathogens to the host.  347 
Although not a resident member of the gut microbiota, several Lactococcus lactis 348 
strains have also been shown to exhibit mucus-binding properties through bacterial surface 349 
proteins such as mucin-binding proteins and pili (as recently reviewed in (Mercier-Bonin & 350 
Chapot-Chartier, 2017)). The mechanisms of adhesion have been extensively studied by 351 
atomic force spectroscopy demonstrating a comparable role played by these two surface 352 
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proteinaceous components in adhesion of L. lactis TIL448 to pig gastric mucin (PGM) neutral 353 
oligosaccharides under static conditions, whereas a more important contribution of the MUBs 354 
than the pili one was observed under shear flow (Le et al., 2013).  355 
 356 
Other cell surface proteins. Other cell surface proteins implicated in the binding of 357 
commensal bacteria to mucin include aggregation-promoting factors (APFs) from L. 358 
plantarum NCIMB 8826 (Bolonkin, 1990) or L. lactis (Lukic et al., 2012, Lukic et al., 2014), 359 
mucus-binding protein A (CmbA) from L. reuteri ATCC PTA 6475 (Etzold et al., 2014, 360 
Jensen et al., 2014), Lam29 from L. mucosae ME-340 (Watanabe et al., 2010), mucus 361 
adhesion-promoting protein (MapA) from L. fermentum/reuteri 104R (Rojas et al., 2002) , a 362 
mucus-binding factor (MBF) from L. rhamnosus GG (von Ossowski et al., 2011, Nishiyama 363 
et al., 2015), a MucBP-containing mannose-specific adhesin protein (Msa) from L. plantarum 364 
WCFS-1 (Pretzer et al., 2005), a 32-Mmubp from L. fermentum BCS87 (Macias-Rodriguez et 365 
al., 2009), an extracellular transaldolase (Tal) from Bifidobacterium bifidum DSM20456 366 
(Gonzalez-Rodriguez et al., 2012) and a recently-characterised serine rich repeat protein 367 
(SRRP) from L. reuteri ATCC 53608 (Sequeira et al., 2018). It is expected that adhesion of 368 
these commensal or probiotic bacteria to mucus may favour their persistence within the gut in 369 
order to exert their beneficial effects to the host. Furthermore, it was recently suggested that 370 
carbohydrate binding modules (CBMs) appended to glycoside hydrolases could contribute to 371 
the tropism of gut bacteria to glycan-rich area of mucins in the colon, as shown for 372 
Ruminococcus gnavus sialic-acid-specific CBM40 (Owen et al., 2017). 373 
 374 
Blood group binding adhesins. In addition, several human enteric pathogens bind to human 375 
histo-blood group antigens (HBGAs) expressed on the gut mucosa, including Campylobacter 376 
jejuni, Norwalk virus and H. pylori. The role of HBGA recognition to mucin binding has been 377 
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extensively studied in the gastric pathogen H. pylori where Helicobacter adhesins have been 378 
reported to play a critical role in the attachment of the pathogen to both the glycosylated 379 
gastric epithelial cell surface and to glycosylated mucins. The binding of H. pylori to gastric 380 
mucins through blood group binding adhesin (BabA) and sialic acid-binding adhesin (SabA) 381 
revealed a complex charge/low pH-dependent mechanism involving four modes of H. pylori 382 
adhesion to MUC5B, MUC7, and MUC5AC mucins (Linden et al., 2008, Skoog et al., 2017). 383 
More recently, a novel outer membrane protein adhesin named LabA has been identified in H. 384 
pylori and shown to bind to LacdiNAc, a structure, which is also expressed on MUC5AC 385 
(Rossez et al., 2014). Binding of H. pylori to gastric mucins therefore is determined both by 386 
the mucin glycosylation and also by the adhesins expressed by individual strains. A chitin-387 
binding protein GbpA from Vibrio cholerae shown to bind to N-acetyl-D-glucosamine 388 
residues of intestinal mucin has been proposed as an important factor mediating intestinal 389 
colonisation and pathogenesis by V. cholerae (Bhowmick et al., 2008, Wong et al., 2012).  390 
 391 
Moonlighting proteins. Unexpectedly, several primarily cytoplasmic proteins have been 392 
reported to play a role in mucin binding. Due to their dual function, these proteins are referred 393 
to as moonlighting proteins (Henderson & Martin, 2011, Henderson & Martin, 2013, 394 
Henderson, 2014). In L. acidophilus, L. plantarum and Mycoplasma genitalium for instance, 395 
the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was clearly demonstrated to play a 396 
role in bacterial adhesion and bind mucins (Alvarez et al., 2003, Kinoshita et al., 2008, Patel 397 
et al., 2016). While the exact domain responsible for mucin binding remains to be elucidated, 398 
GAPDH is suggested to play a similar role in other commensal or pathogenic microorganisms 399 
(Kinoshita et al., 2013). In L. reuteri, elongation factor-Tu (EF-Tu) was found to bind the 400 
PGM when exposed at the bacterial cell surface (Nishiyama et al., 2013). Here, the sulfated 401 
carbohydrate moieties of mucins were demonstrated to play a significant role in EF-Tu-402 
 19 
mediated bacterial adhesion to PGM and mucosal surfaces (Nishiyama et al., 2013). 403 
Proteosurfaceome analyses in a range of microorganisms have revealed a large repertoire of 404 
cytoplasmic proteins present at the bacterial cell surface but their implications in binding to 405 
various extracellular matrix (ECM) proteins, including mucins, remain to be more 406 
systematically investigated (Chagnot et al., 2012, Desvaux et al., 2018). 407 
 408 
2.2. Mechanisms of mucin degradation by commensal and pathogenic 409 
microorganisms in the gut  410 
 411 
 Several enzymatic activities are required for the degradation of mucins by pathogens 412 
or commensal bacteria including glycoside hydrolases (GHs), sulfatases, or proteases (Fig. 1) 413 
as described below.  414 
 415 
Glycoside hydrolases. Mucin glycan degradation in bacteria relies on the expression of GHs 416 
such as sialidases (GHγγ), α-fucosidases (GH29, GH95), exo- and endo-ȕ-N-417 
acetylglucosaminidases (GH84 and GH85), ȕ-galactosidases (GHβ, GHβ0, GH4β), α-N-418 
acetylglucosaminidases (GH89), endo-ȕ1,4-galactosidases (GH98) and α-N-419 
acetylgalactosaminidases (GH101, GH129) (www.cazy.org). These enzymes have been 420 
functionally characterised in resident members of the gut microbiota able to forage on mucins, 421 
including A. muciniphila, B. thetaiotaomicron, B. bifidum, B. fragilis, and R. gnavus, as 422 
recently reviewed (Tailford et al., 2015, Ndeh & Gilbert, 2018). The released mono- or 423 
oligosaccharides derived from mucus degradation by these commensal bacteria can be utilised 424 
by the bacteria itself or scavenged by other bacteria inhabiting the mucus niche including 425 
pathogenic species such as Salmonella species, C. difficile, diarrhoeagenic E. coli, or Vibrio 426 
cholerae through cross-feeding interactions (Fabich et al., 2008, Abyzov et al., 2012, Ng et 427 
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al., 2013). In addition, some of these pathogens have the glycolytic potential to release 428 
mucus-derived sugars for their own consumption (Mondal et al., 2014, Arabyan et al., 2016). 429 
 430 
Sulfatases. Sulfatases are being increasingly investigated for their role in modulating the gut 431 
microbial ecosystem in health and disease. Some members of the gut microbiota such as B. 432 
thetaiotaomicron, Bacteroides ovatus, and Prevotella sp. strain RS2 Bifidobacterium breve 433 
UCC2003, or B. fragilis possess mucin‐ desulfating sulfatases or glycosulfatases (Salyers et 434 
al., 1977, Berteau et al., 2006, Benjdia et al., 2011, Egan et al., 2016, Praharaj et al., 2018). 435 
Mucin sulfatase activity of these species may provide them a competitive advantage in the 436 
infant gut and/or the adult gut. The mucin‐ desulfating sulfatases that have been characterised 437 
so far include sulfatases specific for the ‐ D‐ galactopyranosyl 3‐ sulfate, ‐438 
Dgalactopyranosyl6‐ sulfate, and 2‐ acetamido‐ 2‐ deoxy‐ D‐ glucopyranosyl6‐ sulfate 439 
(6‐ SO3‐ GlcNAc) building blocks of the oligosaccharide chains. GlcNAc-6-S can be found 440 
in terminal or branched positions of mucin oligosaccharide. The desulfation of mucin by 441 
bacterial sulfatases may be a rate-limiting step in mucin degradation mechanism, allowing 442 
glycosidases to access and act on the mucins by other members of the gut microbiota. The 443 
release of sulfate from mucins may also contribute to the expansion of Sulfate-reducing 444 
bacteria (SRB) in the gut (Rey et al., 2013). SRB are able to produce hydrogen sulfide (H2S) 445 
which can reduce disulfide bonds present in the mucus network, leading to mucus erosion and 446 
access of bacteria to the epithelium, therefore contributing to epithelial damage and 447 
inflammation  This mechanism has been proposed to be involved in the aetiology and/or 448 
severity of IBD (Ijssennagger et al., 2016). In addition, Hickey and colleagues showed that 449 
sulfatases of B. thetaiotaomicron are required for its outer membrane vesicles to transit to 450 
underlying host immune cells and cause colitis (Chatzidaki-Livanis & Comstock, 2015). 451 
Together these data highlight the complex role of bacterial sulfatases in the gut. 452 
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 453 
Proteases. Bacterial proteases from commensal or pathogenic E. coli have also been 454 
implicated in the recognition and degradation of mucins. In EHEC, StcE (secreted protease of 455 
C1 esterase inhibitor from EHEC) was originally described as specifically cleaving C1 456 
esterase inhibitor (C1-INH) (Lathem et al., 2002, Grys et al., 2006) but later showed to be 457 
even more active against MUC7 (Lathem et al., 2002). This soluble enzyme is important in 458 
reducing mucin levels. StcE has been suggested to have a dual role during human infection, 459 
(i) by promoting the penetration of bacterial cells through the mucus barrier lining the GI tract 460 
and thus facilitating the intimate EHEC adherence to IECs, which is an essential step in 461 
colonisation (Hews et al., 2017), and (ii) by acting as an anti-inflammatory agent protecting 462 
bacterial and host cell surfaces from complement-mediated lysis (Grys et al., 2005, Abreu & 463 
Barbosa, 2017). StcE is secreted by a Type II, subtype a, secretion system (T2aSS) (Monteiro 464 
et al., 2016, Hay et al., 2018). This mucinase is a metalloprotease belonging to the peptidase 465 
M66 family (IPR019503) carrying one zinc atom per protein but no structural calcium, which 466 
is a reported feature of metalloproteases (Yu et al., 2012). Recently, EHEC StcE 467 
metalloprotease was shown to reduce the inner mucus layer in human colonic mucosal 468 
biopsies and the MUC2 glycoprotein levels in mucin-producing LS174T colon carcinoma 469 
cells (Hews et al., 2017).  470 
Pic (protein involved in intestinal colonisation), also previously known as Shmu 471 
(Shigella mucinase), is a secreted protease identified in Shigella flexneri and 472 
enteroaggregative E. coli (EAEC) (Henderson et al., 1999). Pic is secreted by a Type V, 473 
subtype a, secretion system (T5aSS) and belongs to the subfamily of serine protease 474 
autotransporters (SPATEs), with a catalytic domain corresponding to the peptidase S6 family 475 
(IPR030396). This enzyme was reported to display proteolytic activity against gelatin as well 476 
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as bovine and murine mucin but not hog gastric mucin (Henderson et al., 1999). PicU was 477 
also shown to exhibit mucinolytic activity in uropathogenic E. coli (Parham et al., 2004).  478 
Hbp (hemoglobin-binding protease), also previously known as Tsh (temperature-479 
sensitive haem-agglutinin), is capable of cleaving bovine submaxillary mucin but not hog 480 
gastric mucin, which so far would appear as a feature of mucinolytic serine protease 481 
autotransporter of Enterobacteriaceae (SPATE) of the peptidase S6 family (Dutta et al., 482 
2002). In some EHEC strains, a SPATE of the peptidase S6 family exhibiting mucinolytic 483 
activity was identified on plasmid pO113, namely EpeA (EHEC plasmid-encoded 484 
autotransporter) (Leyton et al., 2003). In AIEC, a Vat (vacuolating autotransporter) 485 
homologue belonging to the SPATE of the peptidase S6 family was demonstrated to exhibit a 486 
mucinolytic activity (Gibold et al., 2016). Vat-AIEC appears to significantly contribute to the 487 
colonisation ability of AIEC by decreasing mucus viscosity as well as enhancing bacterial 488 
penetration in mucus and access to IECs (Gibold et al., 2016). 489 
In some non-O157 EHEC strains, a subtilase cytotoxin (SubAB) was identified (Paton 490 
et al., 2006, Wang et al., 2007) and appeared to contribute to mucin depletion as shown with a 491 
Shiga-toxin encoding E. coli (STEC) O113:H21 strain (Gerhardt et al., 2013). While the A 492 
subunit harbours the enzymatic activity with a subtilase-like serine protease domain 493 
belonging to the peptidase S8/S53 family (IPR000209), the mucinolytic activity of SubAB 494 
remains to be clearly established. 495 
Other proteins have been described in V. cholerae. Among them, TagA is a secreted 496 
protease of V. cholerae that specifically cleaves mucin glycoproteins (Szabady et al., 2011). 497 
The V. cholerae extracellular chitinase ChiA2 secreted in the intestine hydrolyzes intestinal 498 
mucin to release GlcNAc, and the released sugar is successfully utilized by V. cholerae for 499 
growth and survival in the host intestine (Mondal et al., 2014).  500 
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SslE (secreted and surface associated lipoprotein), previously known as YghJ, is a 501 
secreted and cell-surface lipoprotein degrading the major mucins in the small intestine, 502 
namely MUC2 and MUC3, thus facilitating bacterial penetration of the mucus layer and 503 
ultimately adhesion to host cells (Luo et al., 2014, Valeri et al., 2015, Tapader et al., 2017). 504 
SslE is secreted via a T2aSS and appears inactive against the mucin-like CD43, bovine 505 
submaxillary mucin, gelatin, or IgG (Luo et al., 2014). This Zn-metalloprotease, belonging to 506 
the peptidase M60 family (IPR031161), is found in pathogenic and commensal E. coli, 507 
including ETEC, EHEC O104:H4, E. coli SE-11 or Nissle 1917 strains. AcfD (accessory 508 
colonisation factor D) from V. cholerae is homologous to SslE but its putative mucinolytic 509 
activity remains to be investigated (Peterson & Mekalanos, 1988). Of note, SslE is also 510 
considered as a relevant target for the development of vaccines against intestinal pathogenic 511 
E. coli (Nesta et al., 2014, Naili et al., 2016, Naili et al., 2017).  512 
 513 
3. Importance of mucus-bacteria interactions in health and disease 514 
 515 
In the colon, the outer mucus layer offers a niche to commensal bacteria by providing 516 
preferential binding sites (Section 2.1) and nutrients (Section 2.2). Due to its proximity to host 517 
cells and the immune system, the mucus-associated microbiota, sometimes also referred to as 518 
the mucobiome (Belzer et al., 2017), has been proposed as an important modulator of health. 519 
The integrity of the mucosa relies on a combination of factors including the gut microbiota 520 
composition, the diet and host genetic factors (Fig. 2) (Martens et al., 2018). The mucus and 521 
mucus-associated bacterial community play a key role in limiting access of invading 522 
pathogens to the underlying epithelial cells and in limiting the progression of intestinal and 523 
extra-intestinal diseases (Donaldson et al., 2016).  524 
 525 
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Effect of bacteria and bacterial products on mucus production. A number of animal studies 526 
(using antibiotic-treated, germ-free or gnotobiotic mice) suggest that the presence of bacteria 527 
triggers the development of the protective mucus layer. Mice treated with the antibiotic 528 
metronidazole, but not streptomycin, display an altered goblet cell function and thinning of 529 
the inner mucus layer (Wlodarska et al., 2011). However, another study reported that 530 
depletion of the intestinal microbiota following a three week-antibiotic period (cocktail of 531 
four antibiotics) did not modify mucus penetrability (Johansson et al., 2015).  532 
 Compared to conventionally housed animals, germ-free mice have fewer goblet cells, 533 
which are smaller in size (Kandori et al., 1996) and harbour an impaired mucus layer, 534 
indicating that the formation of the protective mucus layer depends upon the presence of 535 
bacteria (Rodriguez-Pineiro & Johansson, 2015). Johansson and colleagues demonstrated that 536 
the mucus of germ-free mice displayed a significant decrease in Muc2 level and was more 537 
penetrable to bacterium-size fluorescent beads as compared to conventionally raised mice 538 
(Johansson et al., 2015). The gut microbiota composition of germ free animals is normalized 539 
two weeks after colonisation in terms of microbiota composition, but up to 8 weeks are 540 
needed to reach a normalized mucus phenotype (Johansson et al., 2015, Hayes et al., 2018). 541 
In support of this, fortification of the mucus layer and increased diversity of mucin 542 
glycosylation was observed within 48 hours of human intestinal organoid colonization with 543 
human-derived, non-pathogenic E. coli (Hill et al., 2017). Some bacteria, in particular 544 
Anaerostipes, have been shown to display mucus-stimulating properties (Jakobsson et al., 545 
2015). Lactobacillus species can also stimulate MUC2 production and secretion by the goblet 546 
cells in the human gut (Sicard et al., 2017). Representative members of the two main phyla of 547 
the gut microbiota, B. thetaiotaomicron and Faecalibacterium prauznitzii can modulate goblet 548 
cell differentiation and thus mucus production (Wrzosek et al., 2013). A recent study showed 549 
that Streptococcus thermophilus, a transient food-borne bacterium, was able to induce mucus 550 
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pathway in gnotobiotic rodents despite its poor capacity for mucus adhesion and mucin 551 
glycan degradation in vitro (Fernandez et al., 2018). Some of the mechanisms mediating 552 
mucin production and secretion by gut bacteria have been elucidated as described below.  553 
Pathogen associated molecular patterns such as lipopolysaccharide (LPS) or 554 
peptidoglycan are known to induce mucus production (Petersson et al., 2011). LPS and 555 
flagellin purified from Gram-negative bacteria as well as lipoteichoic acid from Gram-556 
positive bacteria have been shown to induce mucin upregulation via the Ras-signalling 557 
pathway (McNamara & Basbaum, 2001). LPS also increases the production of interleukin 558 
(IL)-8 by goblet cells, which further promotes mucin secretion (Smirnova et al., 2003). TLR 559 
family members play an important role in mucus formation. Mice lacking the TLR adaptor 560 
protein MyD88 show a decreased production of mucus (Bhinder et al., 2014). Mice 561 
engineered to lack the flagellin receptor, TLR5 deficient mice, have a disorganised mucus 562 
layer and lack a well-defined inner layer when compared to wild type animals with an 563 
increase abundance of Proteobacteria in close contact with the epithelial surfaces (Carvalho et 564 
al., 2012, Chassaing et al., 2014, Chassaing et al., 2015). Lastly, it has been shown in vitro 565 
using various human-derived cell lines that bacterial metabolites such as short-chain fatty 566 
acids (SCFA) and especially butyrate can stimulate MUC2 production in the absence of other 567 
energy sources (Willemsen et al., 2003, Gaudier et al., 2004). The effect of butyrate on 568 
MUC2 gene expression is mediated by epigenetic modifications (acetylation/methylation of 569 
histones) on the MUC2 promoter as demonstrated in vitro using human goblet cell-like 570 
LS174T cells (Burger-van Paassen et al., 2009). Fernandez and colleagues suggested that 571 
lactate produced by S. thermophilus in the GI tract could stimulate mucus production via a 572 
signalling pathway dependent of KLF4, a transcription factor involved in the differentiation 573 
of goblet cells (Fernandez et al., 2018). Some other bacterial effectors have been identified to 574 
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mediate mucin expression and glycosylation such as small peptides from R. gnavus and B. 575 
thetaiotaomicron (see section 2). 576 
 577 
Interactions of pathogens with mucus. The mucus barrier provides a bulwark against 578 
intestinal pathogens (Johansson et al., 2013, Sicard et al., 2017, Martens et al., 2018). The 579 
importance of intestinal mucus in controlling enteric infection has been widely documented in 580 
Muc2 knockout mice (Muc2-/- mice) (see section 4.5), which do not produce mucus in the 581 
small and large intestine, thus leading to a close contact between bacteria and the epithelium. 582 
Bergstrom and colleagues reported that Muc2−/− mice exhibit an increase susceptibility to 583 
murine bacterial pathogen Citrobacter rodentium (Bergstrom et al., 2010). Likewise, Muc2 584 
plays a crucial role in controlling Salmonella infection (Zarepour et al., 2013). In a similar 585 
way, H. pylori has evolved mechanisms allowing its residence in the gastric mucus layer 586 
(Moore et al., 2011). As previously described for bacteria, Muc2−/− mice are also more 587 
susceptible to enteric parasitic infection with Trichuris muris since they exhibit a delayed 588 
expulsion of the parasite compared to wild type animals (Hasnain et al., 2010). Clearance of 589 
parasitic infection is associated with exclusion of helminths via a TH2 cell-mediated goblet 590 
cell increase and mucus release (Artis & Grencis, 2008). Entamoeaba histolytica also 591 
possesses lectins binding to mucins and secretes proteases responsible for the cleavage of 592 
Muc2, allowing the protozoan to invade the underlying epithelium (Lidell et al., 2006). 593 
Recently, a detailed investigation of the cooperative roles for colonic microbiota and Muc2 in 594 
mediating innate host defence against E. histolytica was carried out using Muc2−/− mice, germ 595 
free mice and mucus-secreting LS174T cells, demonstrating that mucus secretion and pro-596 
inflammatory responses were microbiota-specific (Leon-Coria et al., 2018). Lastly, as shown 597 
with S. flexneri and H. pylori, some pathogenic bacteria are able to reshape mucin structures 598 
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by remodelling their glycosylation pattern in a type III secretion system-dependent manner 599 
(Sperandio et al., 2013, Magalhaes et al., 2015). 600 
Emerging data suggest that pathogenic bacteria can benefit from the capacity of 601 
commensal microorganisms to release mucin degradation products that can be used to support 602 
their proliferation within the mucus niche. For example, B. thetaiotaomicron can release free 603 
sialic acid from colonic mucus glycans that can be utilized by C. difficile and Salmonella 604 
Typhimurium to promote their own colonisation and persistence in the gut (Ng et al., 2013). 605 
Another study indicates that EHEC bacteria colonise the mucus layer within the cooperation 606 
of local bacterial communities including B. thetaiotaomicron and other anaerobes which are 607 
able to cleave host glycan- derived sugar and produce fucose (Pacheco et al., 2012). EHEC 608 
then senses fucose produced by B. thetaiotaomicron to control expression of its type III 609 
secretion system (Pacheco et al., 2012, Cameron et al., 2018).  610 
Mucus-pathogen interactions have also been evidenced in the extra-digestive area. 611 
Pseudomonas aeruginosa, a Gram-negative flagellated pathogen, is the main causal agent for 612 
the development of pneumonia in immunocompromised patients and patients with cystic 613 
fibrosis (CF). This infection is associated with a genetic disorder caused by mutations in the 614 
cystic fibrosis transmembrane conductance regulator (CFTR), a chloride and bicarbonate ion 615 
channel protein with a key role in protecting the small intestine from bacterial invasion. CF 616 
conducts to blockage airway, mucus hypersecretion leading to chronic bacterial lung 617 
infections and inflammation. It has been shown that P. aeruginosa, via LPS, upregulate 618 
MUC2 and MUC5AC gene expression contributing to the excessive mucus production and 619 
airway blockage seen in CF (Bellu et al., 2013).  620 
 621 
Effect of diet on mucus. Recent evidences have demonstrated that the diet can influence the 622 
properties of colonic mucus and thereafter interfere with the gut microbiota.  623 
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Fibres. Living in symbiosis with the host, the gut microbiota depends mostly on non-624 
digestible fibres and polysaccharides as energy source. In the absence of fibres in the diet, the 625 
gut microbiota shifts towards the utilisation of host glycans such as those provided by mucins, 626 
resulting in a thinner protective colonic mucus (Sonnenburg & Sonnenburg, 2014, Earle et al., 627 
2015). Accordingly, Desai and colleagues demonstrated that a low-fibre diet promotes the 628 
enrichment of mucin-degrading bacteria and the overexpression of carbohydrate-active 629 
enzymes (CAZymes) that degrade the colonic mucus barrier (Desai et al., 2016, Martens et 630 
al., 2018). In these mice fed with a deprived-fibre diet, infection with C. rodentium promotes 631 
greater epithelial access and lethal colitis (Desai et al., 2016).  632 
A lack of fermentable fibres in the diet also leads to a reduction in epithelial cell 633 
proliferation resulting in a thin mucosa with encroached bacteria (Chassaing et al., 2015). 634 
Further studies in mice reported that inulin supplementation increases the number of colonic 635 
goblet cells, which correlates with a thicker mucus layer and an increase proportion of the 636 
Akkermansia genus (Kleessen et al., 2003, Everard et al., 2013). Similarly, studies in mice 637 
showed that a diet enriched in inulin fibre prevents mucus deterioration (Schroeder et al., 638 
2018). It was recently showed that inulin but not cellulose protects against diet-induced 639 
obesity by reducing microbiota encroachment in a cytokine IL-22-dependent manner (Zou et 640 
al., 2018), demonstrating the importance of dietary factors, especially soluble fibre, in the 641 
homeostasis of host-microbiota relationship. Considering the increased mucus foraging 642 
activity occurring when mice are fed with a low-fibre diet, a recent study showed that 643 
supplementation with probiotic bifidobacteria (B. longum) or prebiotic fibre (inulin) could 644 
reduce such mucus defect. Notably, administration with B. longum was sufficient to restore 645 
mucus growth, while administration with inulin could prevent the increase of mucus 646 
penetrability in mice fed a western style diet (WSD) (Schroeder et al., 2018).  647 
 648 
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Western diet and food additives. Besides fibres, other nutrients within a WSD can 649 
modulate intestinal barrier function. A WSD is a rich in saturated fats and simple 650 
carbohydrates but depleted in dietary fibres. As a result, a diet-induced obesity in mice leads 651 
to colon mucosal barrier dysfunction with a thinner mucus layer (as described above) and 652 
treatment with A. muciniphila appears to counteract this effect by improving mucus thickness 653 
(Everard et al., 2013). Similarly, mice fed a high-fat and high-sugar diet exhibit an increased 654 
abundance of mucin-degrading species leading to a decrease in mucus thickness (Martinez-655 
Medina et al., 2014). The diet of modern societies has dramatically changed as evidenced by a 656 
steady increase in the consumption of processed foods concomitantly with an increase in the 657 
use of food additives (Chassaing et al., 2015). Mice treated with dietary emulsifiers 658 
(polysorbate 80 or carboxymethylcellulose) show a reduced mucus thickness and increased 659 
gut permeability. In these animals, some bacteria appear in close contact with the epithelium. 660 
Emulsifier-treated mice have an altered microbial composition associated with increased 661 
levels of mucolytic bacteria including R. gnavus and a marked reduction in microbial 662 
diversity, with a bloom in Verrucomicrobia phyla, especially A. muciniphila (Chassaing et al., 663 
2015). This may further contribute to the intestinal passage of bacterial constituents such as 664 
LPS and flagellin, which participates in the development of low-grade inflammation and 665 
metabolic disorders in wild type mice and of colitis in susceptible host animals (Chassaing et 666 
al., 2014, Chassaing et al., 2015, Chassaing et al., 2017). Mice fed with diets enriched in 667 
maltodextrin, a filler and thickener used in food processing, show a reduction of Muc2 668 
expression, making the host more sensitive to low-grade inflammation but with no significant 669 
change in mucosa-associated microbiota (Laudisi et al., 2018).  670 
 671 
Effect of food contaminants on mucus. The intestinal mucosa is increasingly appreciated as a 672 
key player in the emerging field of gut toxicology of environmental pollutants, as recently 673 
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reviewed (Gillois et al., 2018). Human contamination mainly occurs via the oral route through 674 
consumption of food but also through polluted water and soil exposure.  675 
Nanomaterials. The use of nanotechnology in many common consumer products, 676 
especially in food products, is growing. Scarce studies have evaluated the interactions of food 677 
nanoparticles with the microbiota and mucus (Mercier-Bonin et al., 2018). It was shown in 678 
vitro that common nanoparticles of Titanium dioxide (TiO2) are trapped into mucus, leading 679 
to areas with a high local concentration (Talbot et al., 2018). Silver nanoparticles are widely 680 
used in food industry to colour the surface of confectionary and pastries. Rats fed with these 681 
particles exhibit higher numbers of goblet cells and a modification of the glycosylation 682 
pattern of mucins with a decreased proportion of sulfated mucins and an increased proportion 683 
of sialyated mucins (Jeong et al., 2010). Repeated silver nanoparticle-exposure may therefore 684 
produce pathological regions in the lamina propria (Jeong et al., 2010). 685 
Persistent Organic Pollutants. A recent study showed that mice chronically exposed 686 
to benzo[a]pyrene (BaP) which is the most toxic member of the polycyclic aromatic 687 
hydrocarbons family display significant shifts in the composition and relative abundance of 688 
stool and mucosa-associated bacterial communities (decrease of Verrucomicrobiaceae, 689 
represented by A. muciniphila) (Ribiere et al., 2016). Furthermore, exposure to 690 
perfluorooctane sulfonate (PFOS, environmental contaminant used as a surfactant and 691 
repellent) in a mouse model of C. rodentium infection led to a significant reduction in mucin 692 
gene expression and a failure to clear the bacterial infection (Suo et al., 2017). Smoke 693 
exposure also significantly affects the mucosa-associated bacterial community and alters the 694 
expression of mucins in the murine gut (Allais et al., 2016). 695 
 696 
Mucus and inflammatory related diseases.  697 
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Inflammatory bowel diseases (IBD). Barrier disturbances including alterations in the 698 
thickness or composition of the intestinal mucus layer are recognized to play a crucial role in 699 
the onset of GI disorders such as Crohn disease (CD) or ulcerative colitis (UC). The mucus 700 
layer in UC patients is thinner and has an altered glycosylation profile making it more 701 
penetrable to bacteria (Johansson et al., 2014). To better understand the onset of IBD, several 702 
murine models of intestinal inflammation (genetically or chemically induced) have been 703 
established. The most common experimental model of colitis relies on the administration of 704 
Dextran Sodium Sulfate (DSS) in the drinking water. Mice orally administered with DSS 705 
display an inner mucus layer which is more penetrable by bacteria within 12 hours (Johansson 706 
et al., 2010). Similarly, IL-10-/- and TLR5-/- mice that develop spontaneous colitis have a 707 
thicker mucus layer and more penetrable inner mucus layer when compared to wild type 708 
animals (Johansson et al., 2014). Muc2-/- mice develop intestinal inflammation with diarrhoea, 709 
rectal bleeding and prolapse (Johansson et al., 2008) and are more susceptible to DSS-710 
induced colitis; these animals exhibit a massive number of bacteria in close contact with host 711 
tissues, further promoting inflammation (Van der Sluis et al., 2006). Moreover, abnormal 712 
mucin O-glycosylation has been associated with an increased inflammation, highlighting the 713 
importance of mucin glycans in the maintenance of gut homeostasis (Johansson et al., 2014) 714 
(Bergstrom & Xia, 2013, Bergstrom et al., 2016). 715 
These changes in mucus composition were also mirrored by changes in the gut 716 
microbiota composition at the mucosal surface. IBD patients exhibit a disproportion of 717 
mucin-degrading (or mucinolytic) bacteria with an increased abundance of Ruminococcus 718 
torques and R. gnavus, but a decreased abundance of A. muciniphila. In addition, the 719 
expansion of certain pathobionts and in particular AIEC exhibiting mucinolytic activity has 720 
been reported to favour gut colonisation and further induce inflammation in CD (Palmela et 721 
al., 2018). Taken together, these data suggest that mucus-bacteria interactions contribute to 722 
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the intestinal barrier dysfunction in IBD patients and future work is needed to better 723 
understand the influence or consequence of these interactions on the disease.  724 
 725 
Obesity and metabolic-related disorders. A correlation between adiposity, 726 
dysglycemia and microbiota encroachment has been reported in a number of animal studies. 727 
Muc2-/- mice fed a High Fat Diet (HFD) are protected from diet-induced weight gain, fatty 728 
liver, and insulin resistance as they displayed less inflammation and increased systemic levels 729 
of IL-22 (Hartmann et al., 2016). This study supports a role of Muc2 during obesity and 730 
highlights the importance of the crosstalk between microbiota, mucus and immune mediators. 731 
In mice fed a HFD, mucus secretion is altered in the ileum but not in the duodenum and 732 
jejunum, largely in response to an alteration of PPAR-Ȗ signalling. In these mice, Muc2 733 
accumulates at the apical side of goblet cells, leading to a reduction in the expansion capacity 734 
of the mucins, thus strongly altering the phenotype of the mucus layer (Tomas et al., 2016). 735 
Studies by Chassaing and colleagues in different mouse models of metabolic syndrome and in 736 
humans demonstrated that bacteria have the ability to infiltrate the mucus layer and reach the 737 
epithelium (Chassaing et al., 2014, Chassaing et al., 2015, Chassaing et al., 2017). Further, 738 
measurement of bacterial-epithelial distance reveals that microbiota encroachment is a feature 739 
of insulin resistance-associated dysglycemia in humans that may promote inflammation 740 
(Chassaing et al., 2017). Several studies demonstrated that A. muciniphila is less abundant in 741 
the intestinal microbiota of both genetic and diet-induced obese and diabetic mice, as well as 742 
in individuals with obesity, when compared to the faecal microbial population of healthy 743 
individuals (Everard et al., 2013, Shin et al., 2014). A. muciniphila treatment has been shown 744 
to reverse fat gain, serum LPS levels, gut barrier function, and insulin resistance. In addition, 745 
oral administration of an outer-membrane protein from A. muciniphila led to reduced fat mass 746 
and metabolic syndrome in mice fed an obesity induced diet (Plovier et al., 2017). 747 
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Conversely, anti-diabetic treatments such as metformin administration led to an increase in 748 
the Akkermansia spp. population (Shin et al., 2014).  749 
Human studies have shown that alcohol abuse induced alcoholic liver diseases (ALD) 750 
are associated with an increase in intestinal mucus thickness in patients, using wheat germ 751 
agglutinin staining on duodenal biopsies (Hartmann et al., 2013). Animal studies 752 
demonstrated that when compared to wild type animals, Muc-2-/- mice are protected from 753 
alcoholic steatohepatitis in an experimental alcohol-induced liver disease model (Hartmann et 754 
al., 2013). In addition, Muc-2-/- mice are protected from Non Alcoholic Fatty Liver Disease 755 
(NAFLD) when fed a high-fat diet inducing liver steatosis (Hartmann et al., 2016). 756 
Altogether, these data highlight the role of mucus and mucins in the gut-liver axis. 757 
 758 
Cancer. The role of mucins in cancer progression has been extensively reviewed 759 
(Hollingsworth & Swanson, 2004, Kufe, 2009). Muc2-/- mice displayed spontaneous 760 
development of adenomas in the small intestine that progressed to invasive adenocarcinoma, 761 
as well as rectal tumours (Velcich et al., 2002). In humans, high levels of expression of 762 
MUC2 by pancreatic and biliary tumours has been associated with a low degree of 763 
invasiveness, malignancy and a better prognosis as compared to tumours not expressing 764 
MUC2 (Hollingsworth & Swanson, 2004). An abnormal mucin O-glycosylation has been 765 
associated with an increased inflammation that could contribute to the development of colitis-766 
associated colon cancer in mice (Bergstrom & Xia, 2013, Bergstrom et al., 2016). Together 767 
these studies support the role of MUC2 as a tumour suppressor. 768 
 769 
4. Potential of experimental models to study mucus/mucin interactions with gut 770 
microbes 771 
 772 
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As mounting evidences highlight the importance of mucus in the cross-talk between 773 
the gut microbiota and the host, a wide range of experimental models has been developed to 774 
study mucus-bacteria interactions (Table 1). These include the use of purified mucins, mucin-775 
secreting cells or tissues, or mucin-containing fermentation models, as described below. 776 
 777 
4.1. In vitro mucus/mucin binding assays  778 
 779 
Microplate assays. Several microtiter plate assays have been developed for testing bacterial 780 
adhesion to mucus and/or mucin (McNamara et al., 2000, Gusils et al., 2004). These 781 
generally rely on the immobilisation of mucins or mucus to the wells of microtiter plates 782 
following incubation overnight at 4°C or at room temperature in buffers such as such as PBS 783 
(pH 7-7.5), HBSS (pH 7-7.5) or carbonate buffer (pH 9.6) (Gusils et al., 2004, Dague et al., 784 
2010, Mackenzie et al., 2010, Chagnot et al., 2013). BSA (bovine serum albumin) is 785 
generally used as a negative control for assessing the specificity of the binding to mucus 786 
and/or mucin. Binding assays are usually performed at 37°C and the contact time with 787 
bacterial cells generally ranges between 30 min to 3 hours before washing to remove non-788 
adhered bacteria. Antibiotic at growth inhibiting concentration, such as chloramphenicol, or 789 
sometimes thermic treatment can be applied to prevent the growth of microorganisms in the 790 
course of the adhesion assay. Binding can be determined using crystal violet staining of the 791 
adhered microbial biomass (Azeredo et al., 2017) or by Enzyme-linked Immunosorbent 792 
Assay (ELISA) when specific antibodies against bacteria are available (Skoog et al., 2012), 793 
by measurement of viable counts after plating of the cells (McNamara et al., 2000) or by 794 
quantitative PCR (Skoog et al., 2012). Alternatively, bacteria can be labelled with a 795 
radioactive probe or a fluorescent dye before inoculation and the binding quantified using a 796 
scintillation counter or a fluorometer, respectively (Gusils et al., 2004, Mackenzie et al., 797 
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2010). Microbial cells can also be labelled by biotinylation and further assayed using 798 
streptavidin-HRP by ELISA (Sheng et al., 2012). Quantification of microbial binding to 799 
mucin can also be performed by flow cytometry, where microbial cells are put in contact with 800 
mucin labelled with a fluorescent tag (de Repentigny et al., 2000). 801 
 802 
Dot blot assay. More recently, a dot-blot method was developed for the sensitive and rapid 803 
detection of microorganisms able to bind to mucins (Ringot-Destrez et al., 2018). In brief, 804 
purified mucins were spotted on a nitrocellulose membrane, whereas the bacterial cells were 805 
labelled using a fluorescent dye, such as 4',6-diamidino-2-phenylindole (DAPI), Syto9 or 806 
Fluorescein isothiocyanate (FITC), before being overlaid (Ringot-Destrez et al., 2018). The 807 
adhesion capacities of the microorganisms tested differed depending on the nature of the 808 
mucins including purified GI tract mucins, PGM and mucins from the mucus-secreting cell 809 
line such as HT29-MTX (see detailed description of this cell line in Section 4.2) (Ringot-810 
Destrez et al., 2018).  811 
 812 
Mucin microarrays. The carbohydrate microarray technology offers a powerful platform 813 
where natural or synthetic glycans are immobilized onto a solid support. (Poole et al., 2018). . 814 
Microarrays incorporating mucins from various sources onto different chips surfaces provide 815 
a high-throughput approach to screen bacteria-mucin interactions as well as identify glycan-816 
binding proteins and glycan epitopes involved in this interaction (Clyne et al., 2017). For 817 
example, the use of mucin microarrays revealed that C. jejuni and H. pylori recognised 818 
distinct mucin receptors despite being closely related phylogenetically (Naughton et al., 819 
2013). Recently, H. pylori was shown to interact with trefoil factor family (TFF) protein 820 
TFF1 (Reeves et al., 2008), and that TFF1 specifically interacts with human gastric mucin but 821 
not with human colonic mucins nor mucins from other animal sources as shown using mucin 822 
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microarrays (Dunne et al., 2018). This indicates that TFF1 may play an important role in the 823 
development of gastric cancer in H. pylori infections (Reeves et al., 2008, Dunne et al., 824 
2018). Mucin microarrays were also used to identify the interactions of commensal strains 825 
with mucus (Lactobacillus salivarius AH102 and Bifidobacteria longum AH1205), 826 
highlighting the importance of mucin glycans in the preference of the two bacteria to mucins 827 
(Naughton et al., 2013, Flannery et al., 2015). 828 
 829 
Binding assays in flow chamber. As a consequence of fluid shear gradient in the gut, the 830 
bacteria located in the outer mucus layer are exposed to a more turbulent flow compared to 831 
those that reside between the microvilli of the epithelial cells and therefore less exposed to 832 
physical perturbation (De Weirdt & Van de Wiele, 2015). While the assays described above 833 
correspond to adhesion under static conditions, experiments can also be performed in 834 
dynamic conditions using flow chamber, where the shear force can be controlled (Le et al., 835 
2013). Low-fluid shear environments and high shear rates are known to provide laminar 836 
pattern. Over time and with different laminar flow rates, the surface coverage of microbial 837 
cells to coupons coated with mucin provides an estimate detachment profile as a function of 838 
the shear stress.  839 
 840 
Biophysical assays. In order to gain further molecular insights into the interactions of 841 
microbial cells with mucin, various biophysical techniques have been developed and applied 842 
over the years. Optical biosensors based on resonant mirrors have been used to determine the 843 
binding kinetics of H. pylori cells to mucin (Hirmo et al., 1999). Following competition 844 
binding assays, the recognition of sialylated and sulphated moieties of mucin by H. pylori was 845 
demonstrated. Surface plasmon resonance (SPR) has been used to evaluate the adhesion 846 
abilities of a range of Lactobacillus species (Uchida et al., 2004, Kinoshita et al., 2007). In 847 
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these studies, human colonic mucin (HCM) was immobilised on the sensor chip whereas 848 
bacterial cells were eluted as analytes. Using sialidase or sulfatase, it was further possible to 849 
discriminate some strains of lactobacilli and bifidobacteria that could specifically bind to the 850 
sialic acid or sulphate residues of HCM respectively (Huang et al., 2013). Single-cell force 851 
spectroscopy (SFCS) has been used to quantify the adhesion forces of L. rhamnosus with 852 
mucin at a single-cell level, pinpointing heterogeneities in the bacterial population (Sullan et 853 
al., 2014). More recently, further molecular details of mucin-bacteria interactions were 854 
investigated using atomic force microscopy (AFM). Such an approach was used for the first 855 
time to accurately quantify the force of adhesion of L. lactis cells immobilised on the AFM tip 856 
to PGM at nanoscale level (Dague et al., 2010). Surprisingly, it was found that PGM coating 857 
strongly reduced the bacterial adhesion force compared to bare polystyrene, highlighting the 858 
interplay between electrostatic, hydrophilic and steric repulsions, and that both specific and 859 
non-specific interactions need to be considered (Dague et al., 2010). These results were 860 
consistent with a previous investigation of the muco-adhesive properties of L. lactis using 861 
quartz crystal microbalance with dissipation monitoring (Le et al., 2012). Using bacteria 862 
mutant strains, AFM was also used to provide molecular insights into the respective role and 863 
contribution of mucus-binding proteins and surface organelles (pili or flagella) in muco-864 
adhesion (Le et al., 2013). Interactions at the protein-protein level were further investigated 865 
by AFM to study the adhesive properties of L. reuteri Mub with mucins (Gunning et al., 866 
2016). 867 
 868 
4.2. In vitro mucin-secreting cell models 869 
 870 
Monoculture models. While many colon carcinoma cell lines express mRNAs encoding 871 
surface-associated and/or secreted intestinal mucins (Deplancke & Gaskins, 2001), few of 872 
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them secrete MUC2 or form a mucus layer (Linden et al., 2007, Navabi et al., 2013, Hews et 873 
al., 2017). Most mucus-secreting cell lines are derived from the heterogeneous 874 
adenocarcinoma cell line HT-29 which can be differentiated into a mucus-secreting phenotype 875 
by growth under metabolic stress conditions. After an initial phase of cell mortality, adapted 876 
subpopulations of highly differentiated cells emerge (Lievin-Le Moal & Servin, 2013). HT29-877 
18N2 cells are often used as a model system for goblet cell differentiation and mucin 878 
secretion; these cells have been established by growth under glucose deprivation in galactose-879 
containing culture medium (Phillips et al., 1988). In contrast, HT29-MTX cells and their 880 
clonal derivatives have been obtained by sequential adaptation to increasing concentrations of 881 
methotrexate (Lesuffleur et al., 1990). When grown on Transwell filter supports, some HT-29 882 
MTX clones (e.g. MTX-D1 and MTX-E12) form polarised monolayers mostly constituted of 883 
mature goblet cells secreting an adherent mucus layer of 50-150 µm thickness as revealed by 884 
Alcian Blue staining (Behrens et al., 2001). In addition, the mucin-secreting clonal cell line 885 
HT-29.cl16E emerged from parental HT-29 cells after subculture in sodium butyrate whilst 886 
HT29-FU cells were established by treatment with 5-fluorouracil (Lesuffleur et al., 1991).  887 
These mucus-producing HT-29 derivatives have been widely used to investigate the 888 
adherence of commensal and pathogenic bacteria to host cells (Coconnier et al., 1992, Bernet 889 
et al., 1993, Eveillard et al., 1993, Bernet et al., 1994, Kerneis et al., 1994, Favre-Bonte et al., 890 
1999, Gopal et al., 2001, Schild et al., 2005, Barketi-Klai et al., 2011, Dolan et al., 2012, 891 
Gagnon et al., 2013, Naughton et al., 2013, Martins et al., 2015, Martins et al., 2016) and/or 892 
evaluate the effect of commensal bacteria on infection with enteropathogens (Bernet et al., 893 
1993, Bernet et al., 1994, Coconnier et al., 1998, Gopal et al., 2001, Alemka et al., 2010, 894 
Zihler et al., 2011, Zivkovic et al., 2015, Vazquez-Gutierrez et al., 2016). Some studies 895 
investigated the direct effect of commensal or pathogenic bacteria on host cell mucin 896 
synthesis and/or composition of the mucus layer. Infection with atypical EPEC increased 897 
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expression of secreted MUC2 and MUC5AC as well as membrane-bound MUC3 and MUC4 898 
in HT29-MTX cells, thereby enhancing bacterial growth by providing nutrients for adherent 899 
bacteria (Vieira et al., 2010). Another study showed that apical infection with Listeria 900 
monocytogenes stimulated mucus secretion by polarised HT29-MTX cells. This effect was 901 
mediated by binding of the toxin listeriolysin O to a receptor on the epithelial brush border 902 
(Coconnier et al., 1998) and reduced bacterial invasion and colonisation of the host 903 
epithelium (Lievin-Le Moal et al., 2005). Interestingly, probiotic Lactobacillus strains which 904 
adhering to mucus-producing HT-29 cells upregulated the transcription and secretion of 905 
MUC3 which reduced adherence of EPEC in co-incubation experiments (Mack et al., 2003). 906 
Modulation of mucus production and mucin glycosylation by commensal bacteria can also 907 
occur independently of adhesion. For example, a small soluble peptide of the gut commensal 908 
R. gnavus E1 strain has been shown to increase HT-29 MTX cell glycosylation via enhanced 909 
transcription of glycosyltransferases and MUC2-encoding genes (Graziani et al., 2016). 910 
Similarly, a soluble low molecular weight compound from B. thetaiotaomicron has been 911 
reported to enhance galactosylation in HT29-MTX cells. While no change in transcription 912 
was detected, galactosyltransferase activity was increased in HT29-MTX cells treated with 913 
soluble bacterial extract suggesting post-translational mechanisms of regulation (Miguel et 914 
al., 2001).  915 
In addition to HT-29 cell derivatives, mucus-producing LS174T colon carcinoma cells 916 
have been used to study host-bacteria interactions. LS174T cells secrete mature MUC2, 917 
MUC5AC and human gallbladder mucin (van Klinken et al., 1996) but do not produce an 918 
organised adherent mucus layer (Navabi et al., 2013). Recent studies using this cell line 919 
showed that the secreted metalloprotease StcE reduced MUC2 levels during infection with 920 
EHEC and thereby facilitated bacterial adherence to the intestinal epithelium (Hews et al., 921 
2017). In addition, the soluble protein p40 from L. rhamnosus GG stimulated MUC2 mRNA 922 
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and protein expression in LS174T cells, and this effect was dependent on the epidermal 923 
growth factor receptor (Wang et al., 2014). Furthermore, treatment with butyrate, a product of 924 
bacteria fermentation, increased mucin production in LS174T cells (Burger-van Paassen et 925 
al., 2009, Jung et al., 2015). Recently, LS174T cells were used to decipher E. histolytica-926 
elicited suppressed goblet cell transcription (Leon-Coria et al., 2018).  927 
 928 
Co-culture models. To model human intestinal epithelia, mixed cultures of enterocyte-like 929 
Caco-2 cells and mucus-producing HT29-MTX cells have been widely used in drug 930 
absorption and permeability studies (Hilgendorf et al., 2000, Lozoya-Agullo et al., 2017). Co-931 
cultures prepared with different ratios of Caco-2 and HT29-MTX cells seeded out on 932 
Transwell inserts formed a continuous mucus layer similar to cultures of HT-29-MTX cells 933 
grown alone (Poquet et al., 2008, Beduneau et al., 2014). Notably, the probiotic strains L. 934 
rhamnosus GG or bifidobacteria as well as pathogenic strains of E. coli or L. monocytogenes 935 
adhered better to mucus-deficient Caco-2 cells than to mucus-producing HT-29MTX cells or 936 
Caco-2/HT-29 co-cultures (Laparra & Sanz, 2009). Considering the “closed” oxygen-937 
restricted environment in the human gut, Chen and colleagues developed a 3D porous silk 938 
scaffolding in the shape of a hollow tube. While the inner tube wall was coated with Caco-939 
2/HT29-MTX epithelia, primary human intestinal myofibroblasts were grown in the tube 940 
scaffold space underneath to support epithelial growth and differentiation. Notably, epithelia 941 
grown on 3D scaffolds demonstrated increased MUC2 production compared to Transwell 942 
cultures resulting in the formation of a mucus layer of 11-17 μm thickness (Chen et al., 2015). 943 
 944 
Organ-on-a-chip. Another approach to simulate a mucin-producing human intestinal 945 
epithelium is the ‘Gut-on-a-Chip’ system, where Caco-2 cells are grown on a porous 946 
membrane support in a microfluidic device. While the cell membrane support is maintained 947 
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under cyclic strain mimicking peristaltic motion, the chambers above and below the cell 948 
membrane are constantly perfused with medium, thereby generating low shear stress. This 949 
environment stimulates the formation of 3D intestinal villi similar to those found in the small 950 
intestine (Kim et al., 2012), and the differentiation of Caco-2 cell into absorptive enterocytes, 951 
and also includes enteroendocrine cells, Paneth cells and mucus-producing goblet cells (Kim 952 
& Ingber, 2013). In addition, Caco-2 epithelium grown in the Gut-on-a-Chip model display 953 
enhanced barrier function and mucus production as compared to static Caco-2 cell cultures 954 
(Kim & Ingber, 2013). This system has recently been developed further to allow co- culture 955 
with strict anaerobes (Shin et al., 2019). Although the Gut-on-a-Chip devices have been 956 
mostly used for long-term co-culture of IECs with commensal microbes under healthy 957 
conditions, they are now being employed to model intestinal inflammation (Kim et al., 2016). 958 
Using a Gut-on-a-Chip model, the pathophysiological manifestation and dysregulated barrier 959 
function observed during inflammation could be recapitulated which may help to gain insights 960 
into disease mechanisms and assess potential therapeutic strategies (Shin & Kim, 2018). 961 
Notably, probiotic VSL#3 targeted restoration of the mucosal barrier did not effectively 962 
control the local inflammation nor improve mucus production (Shin & Kim, 2018). The 963 
HuMix (Human Microbial Cross-talk) model is another microfluidic device enabling the co-964 
culture of Caco-2 cell monolayers with commensal bacteria under anaerobic conditions. In 965 
contrast to the Gut-on-a-Chip system, the epithelial cells which do not produce mucus are 966 
separated from the bacteria by a membrane coated with porcine gastric mucin (Shah et al., 967 
2016). 968 
 969 
 970 
4.3. Ex vivo organ cultures  971 
 972 
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As described above, traditional culture of human cells represents a valuable predictor of 973 
human physiology, pathology, and therapeutic responses but is limited by the absence of the 974 
tissue microenvironment. Culture approaches using human intestinal biopsy samples therefore 975 
represent an upscale platform to investigate the involvement of the mucus layer in healthy 976 
conditions or in the onset of various diseases.  977 
 978 
In vitro organ culture (IVOC). In 1969, Browning and Trier were the first to establish a 979 
technique to culture human mucosal biopsies ex vivo. By using a specific culture medium and 980 
incubation of the samples in 95% O2, 5% CO2 at 37°C, mucosal biopsies from the duodeno-981 
jejunal junction were kept alive for up to 24 hours demonstrating epithelial cell proliferation, 982 
fat absorption and active mucus secretion by goblet cells (Browning & Trier, 1969). The 983 
advantages of IVOC of intestinal biopsies versus cell line culture models include the presence 984 
of healthy non-transformed cells including all major IEC types (enterocytes, goblet cells, 985 
Paneth cells and neuroendocrine cells), underlying basement membrane and mucosal tissue, 986 
and the production of mucus. While it is problematic to maintain the loose outer mucus layer 987 
of colonic biopsies during sampling, the inner colonic and small intestinal mucus layers are 988 
generally well preserved as evidenced by microscopy (Haque et al., 2004, Walsham et al., 989 
2016, Hews et al., 2017). IVOC of biopsy samples has been used to investigate adherence of 990 
pathogenic bacteria such as EPEC (Knutton et al., 1987, Schüller et al., 2007), EHEC 991 
(Phillips et al., 2000, Fitzhenry et al., 2002, Lewis et al., 2015), ETEC (Knutton et al., 1989, 992 
Baker et al., 1997) and C. jejuni (Grant et al., 2006) to human intestinal mucosa. In addition, 993 
IVOC demonstrated cytotoxic effects of bacterial toxins, such as Pet toxin from EAEC 994 
(Henderson et al., 1999), Shiga toxin from EHEC (Schüller et al., 2004) and C. difficile toxin 995 
A (Mahida et al., 1996) on intestinal epithelium or mucosa. Interactions of enteropathogenic 996 
bacteria with mucus production were observed in small intestinal and colonic biopsy tissue 997 
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infected with EAEC where bacteria were predominantly associated with a thick mucus layer 998 
above the epithelium, which was not present in non-infected control samples (Hicks et al., 999 
1996, Andrade et al., 2011). This suggests that EAEC stimulates mucus secretion which 1000 
agrees with the production of mucoid stools during EAEC diarrhoea (Croxen et al., 2013). 1001 
Similarly, stimulation of mucus secretion and bacterial binding to the mucus layer were 1002 
observed in biopsy samples from the terminal ileum infected with S. Typhimurium. This was 1003 
followed by Salmonella adherence and invasion of the epithelium accompanied by ruffling of 1004 
the host cell membrane (Haque et al., 2004). Recently, the IVOC system was used to show 1005 
that the metalloprotease StcE diminishes the inner mucus layer and enhances EHEC 1006 
adherence to human colonic biopsy epithelium (Hews et al., 2017).  1007 
 1008 
Polarised IVOC (pIVOC). While the traditional IVOC system allows bacterial access 1009 
to the mucosal and submucosal side of the biopsy, polarised organ culture models have been 1010 
developed which limit bacterial contact to the mucosal side of the tissue. This is particularly 1011 
relevant when studying host responses to bacterial infections where artificial interactions with 1012 
immune cells in the lamina propria might confound experimental readouts. Using a pIVOC 1013 
approach by mounting colonic tissue explants between two Perspex disks in a Snapwell plate, 1014 
Raffatellu and colleagues demonstrated that Salmonella Typhi reduced mucosal expression of 1015 
the pro-inflammatory cytokine interleukin (IL)-8 by production of a capsule which masked 1016 
pathogen-associated molecular patterns such as LPS and flagellin (Raffatellu et al., 2005). In 1017 
addition, pIVOC showed that apical exposure to EPEC or purified H6 flagellin induced IL-8 1018 
expression in duodenal biopsies (Schüller et al., 2009). Furthermore, infection with C. jejuni 1019 
stimulated the production of reactive oxygen species (ROS) in duodenal and colonic mucosa 1020 
(Corcionivoschi et al., 2012). The pIVOC system has also been used to study the interaction 1021 
of probiotic bacteria with mucosal tissue, and incubation of duodenal explants with L. reuteri 1022 
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demonstrated localisation of bacteria in the mucus layer but not in the epithelium. 1023 
Nevertheless, pre-incubation with L. reuteri reduced EPEC adherence to the epithelium 1024 
(Walsham et al., 2016). A different approach to restrict bacterial access to the epithelial 1025 
surface was developed by Tsilingiri and colleagues by gluing a perspex cylinder to the 1026 
mucosal side of colonic resection tissue (Tsilingiri et al., 2012). Surprisingly, apical 1027 
incubation with probiotic L. plantarum resulted in degeneration of mucosal tissue from 1028 
healthy donors, whilst all three strains studied (L. paracasei, L. rhamnosus, L. plantarum) 1029 
caused tissue damage in resections from patients with IBD. In contrast, supernatants from L. 1030 
paracasei reduced inflammation in Salmonella-infected and IBD tissue. As the maintenance 1031 
of larger tissue samples requires incubation in high levels of oxygen (95-99%), the use of 1032 
IVOC to study interactions of oxygen-sensitive bacteria with human intestinal mucosa 1033 
remains problematic. However, a novel murine 3D-intestinal organ culture system was 1034 
recently developed whereby an intact intestinal fragment was luminally perfused with de-1035 
gassed medium containing anaerobic bacteria while the serosal side of the tissue was 1036 
maintained under humidified oxygenated conditions. Whilst preserving gut tissue 1037 
architecture, the system also supported the growth of commensal microbes (Clostridium 1038 
ramosum and SFB) and allowed assessment of their impact on the immune and nervous 1039 
system (Yissachar et al., 2017). 1040 
 1041 
Human enteroids/colonoids and intestinal organoids. New technologies have been 1042 
developed which enable the generation of self-propagating spheres of primary intestinal 1043 
epithelial cells (“mini-guts”). Enteroids or colonoids are derived from adult stem cells isolated 1044 
from the crypts of human small intestinal or colonic tissue, respectively (Jung et al., 2011, 1045 
Sato et al., 2011). In contrast, human intestinal organoids (HIOs) are established by 1046 
differentiation of embryonic or, more often, induced pluripotent stem cells (genetically 1047 
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reprogrammed adult stem cells) (Spence et al., 2011). In comparison to enteroids, HIOs lack 1048 
maturation and more closely resemble foetal than adult intestine. In addition, they are devoid 1049 
of functional intestinal stem cells and surrounded by a mesenchyme which is absent in 1050 
enteroids (Sinagoga & Wells, 2015, Leslie & Young, 2016). As the apical side of the 1051 
epithelium is facing inwards, infection of spheroid enteroids/HIOs with bacteria requires 1052 
microinjection. Studies on the anaerobic pathogen C. difficile showed that injected bacteria 1053 
remained alive in HIOs for up to 12 hours and caused disruption of epithelial barrier function 1054 
via secretion of the toxin TcdA. Interestingly, oxygen measurements indicated reduced 1055 
oxygen levels in the lumen of HIOs (5 to 15%). Furthermore, infection with C. difficile 1056 
resulted in reduced MUC2 and mucus production in HIOs (Engevik et al., 2015). HIOs also 1057 
supported growth of EHEC and commensal E. coli. Infection with EHEC induced ROS 1058 
production and an inflammatory response associated with recruitment of external neutrophils 1059 
into HIO spheres (Karve et al., 2017). Interestingly, colonisation of HIOs with commensal E. 1060 
coli (ECOR2) stimulated enterocyte maturation, antimicrobial peptide secretion, production 1061 
of a MUC2-containing mucus layer, and increased epithelial barrier function, thereby 1062 
indicating the establishment of stable host-microbe symbiosis (Hill et al., 2017).  1063 
To facilitate incubations with bacteria, 2D enteroid systems have now been 1064 
successfully developed where primary intestinal cells are grown as monolayers on permeable 1065 
membrane supports. Previous studies showed that differentiated human enteroid and colonoid 1066 
monolayers contained MUC2-producing goblet cells and formed a mucus layer of more than 1067 
β5 μm thickness (VanDussen et al., 2015, In et al., 2016). Two-dimensional enteroids and 1068 
colonoids supported binding of EAEC, EHEC and EPEC (VanDussen et al., 2015). More 1069 
specifically, apical EHEC infection of colonoids resulted in the formation of characteristic 1070 
attaching and effacing lesions, mucus degradation and reduced expression of the microvillar 1071 
protein protocadherin 24, which was mediated by the secreted serine protease EspP (In et al., 1072 
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2016). The 2D enteroid model was further refined by adding primary human macrophages to 1073 
the basolateral side of the membrane support. Intriguingly, enteroid monolayers grown in the 1074 
presence of macrophages exhibited increased cell height and barrier function. In addition, 1075 
underlying macrophages were able to capture and kill EPEC and ETEC by extending 1076 
projections across the epithelial monolayer (Noel et al., 2017).  1077 
 In another approach to mimic the gut environment more closely, cells from human 1078 
small intestinal enteroids were seeded on tubular silk sponge scaffolds and supported by 1079 
primary human intestinal myofibroblasts as described for Caco-2/HT29-MTX (Section 4.2). 1080 
The resulting intestinal model epithelium contained all four major epithelial cell types and 1081 
exhibited tight junction formation, microvillus polarisation, digestive enzyme secretion, and 1082 
low oxygen tension in the lumen. Moreover, infection with a laboratory strain of E. coli 1083 
resulted in a significant innate immune response (Chen et al., 2017). Recently, a Gut-on-a-1084 
Chip model based on primary intestinal epithelial cells has been developed which also 1085 
includes co-culture of an underlying endothelium. Human enteroids are cultured on a side of a 1086 
porous membrane within a microfluidic device whereas the intestinal microvascular 1087 
endothelium is established on the other side of the filter.. This device reproduces the epithelial 1088 
cells proliferation and host defenses more accurately (Kasendra et al., 2018). Kim and 1089 
colleagues showed that a human  Gut-on-a-Chip micro device colonized by non-pathogenic 1090 
bacteria (commensal  and probiotic bacteria) was able to induce production of a key set of 1091 
pro-inflammatory cytokines. This device enabled high level of mucus production on micro 1092 
engineered intestinal villi, therefore providing a protective barrier to maintain long-term 1093 
stable host–microbe coexistence (Kim et al., 2016). 1094 
 1095 
4.4. In vitro human fermentation models involving a mucosal phase 1096 
 1097 
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As aforementioned, the spatial positioning of gut microorganisms in the mucus layer is 1098 
important with respect to their functional role in the human gut ecosystem. The microbial 1099 
community residing in the mucus layer across the length of the GI tract is, however, hard to 1100 
study given the difficulty to sample this region in vivo, especially in human (Macfarlane et al., 1101 
1997, Flint et al., 2012, Donaldson et al., 2016). In vitro colonic models involving a mucosal 1102 
phase are a valuable alternative to study the fine-scale spatial organisation of the gut 1103 
microbial ecosystem.  1104 
Multiple colon in vitro models have been developed over the years, ranging from 1105 
simple, single stage batch incubations to more complex and representative three stage 1106 
continuous and semi-continuous reactor models (Miller & Wolin, 1981, Gibson et al., 1988, 1107 
Allison et al., 1989, Blanquet-Diot et al., 2012, McDonald et al., 2013, Van den Abbeele et 1108 
al., 2013). These continuous fermentation models, inoculated with faecal samples of donors, 1109 
recapitulate the main biotic and abiotic parameters of the human colon, such as temperature, 1110 
pH, residence time, supply of nutritive medium reproducing the composition of ileal effluents, 1111 
therefore enabling the study of a complex and metabolically active gut microbiota under 1112 
anaerobiosis conditions. In these fermentation models, the bioreactors can be inoculated with 1113 
fresh or frozen stools provided by individual or pool of different donors being healthy human 1114 
volunteers with no history of antibiotic treatment 2 to 6 months before the beginning of the 1115 
study. 1116 
 1117 
Introduction of mucus carriers in human in vitro colonic models. Mucins in solution have 1118 
been frequently included in these colonic models to provide a nutrient source to the gut 1119 
bacteria, but the study of mucus colonisation by gut bacteria in these systems has been 1120 
revolutionized by the ability to simulate the viscoelastic gel-like nature of the mucus layer 1121 
through the incorporation of mucus carriers (Gibson et al., 1988, Macfarlane et al., 1989, 1122 
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Macfarlane et al., 2005, Van Herreweghen et al., 2017). MacFarlane first demonstrated a 1123 
rapid colonisation of an agar-mucus layer during a 48-hour incubation in a two-stage 1124 
continuous fermentor system by a mixture of Bacteroides, enterobacteria and facultative 1125 
anaerobes (Macfarlane et al., 2005). However, the use of glass tubes, containing this agar-1126 
mucus layer, in this set-up did not permit a practical long-term implementation (Van den 1127 
Abbeele et al., 2009). Mucus-coated beads (mixture of 5% porcine mucin type II and 1% 1128 
agar) have since been identified as crucial platforms in sustaining microbial diversity by 1129 
selectively enriching species, which are not thriving in the luminal environment. This mucus 1130 
interphase was introduced in the Simulator of the Human Intestinal Microbial Ecosystem 1131 
(SHIME) resulting in the M-SHIME (Mucus SHIME) configuration (Van den Abbeele et al., 1132 
2012). This system was first used to assess the fitness of potential probiotic lactobacilli, 1133 
revealing a pronounced enrichment of Lactobacillus mucosae and L. rhamnosus GG in the 1134 
mucus beads compared to the luminal environment, contributing to their long-term 1135 
persistence in M-SHIME (Van den Abbeele et al., 2012). The use of next-generation 16S 1136 
rRNA gene amplicon sequencing methods and the incorporation of mucus beads in both 1137 
proximal and distal colon conditions in the M-SHIME, further resulted in the detection of 1138 
several additional mucus-associated species (De Paepe et al., 2018). Besides Roseburia 1139 
faecis/Enterococcus rectale, a strong enrichment of Ruminococcus inulinivorans, 1140 
Clostridium, Bilophila, Anaeroglobus and Veillonellaceae species was observed in the 1141 
proximal mucus layer compared to the lumen (De Paepe et al., 2018). A. muciniphila, 1142 
Cloacibacillus evryensis, Pyramidobacter piscolens, Eubacterium contortum and species 1143 
belonging to Odoribacter, Enterobacteriaceae and Desulfovibrio were predominantly 1144 
residing in the distal mucus layer (De Paepe et al., 2018). It can be expected that the list of 1145 
species inhabiting the mucus layer will continue to expand in the future M-SHIME 1146 
experiments, by continuing to explore the inter-individual variability of faecal samples. 1147 
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Another major advantage of in vitro fermentation models is the possibility to capture 1148 
dynamics by time-resolved analyses. To minimize disturbance of the system during such 1149 
analyses, the M-SHIME system was adapted to facilitate a rapid, anaerobic, frequent 1150 
sampling by mounting sampling ports with an airlock system on top of the SHIME lids. These 1151 
sampling ports moreover enable the anaerobic addition, transfer and sampling of any 1152 
insoluble dietary substrate. The adapted model was correspondingly termed Dietary Particle-1153 
Mucosal-Simulator of the Human Intestinal Microbial Ecosystem (DP-M-SHIME). The DP-1154 
M-SHIME offers a closer proxy for the diversity of in vivo GI microenvironments, as aside 1155 
from the mucus layer, insoluble dietary particles present an interesting additional niche for 1156 
microorganisms to physically interact with and colonise (De Paepe et al. 2018). 1157 
 In addition, these colonic in vitro fermentation models enable the study of severe gut 1158 
microbiome perturbations such as antibiotic therapy or pathogen invasion, which cannot be 1159 
performed in humans for obvious ethical reasons. Using M-SHIME, the mucus bead carriers 1160 
were shown to confer resilience to lactobacilli species against a combined treatment of 1161 
antibiotics including tetracycline, amoxicillin and ciprofloxacin (Van den Abbeele et al., 1162 
2012). In addition, the M-SHIME model has been used to demonstrate the antagonistic effects 1163 
of probiotics and prebiotics such as L. reuteri, long-chain arabinoxylans or inulin towards 1164 
AIEC colonisation in the mucosal environment (Van den Abbeele et al., 2016). Another study 1165 
reported the importance of mucus for providing a protective environment to beneficial gut 1166 
microbes, such as L. reuteri, to help them escape from stress induced by high loads of linoleic 1167 
acid, the most common polyunsaturated fatty acid in a WSD (De Weirdt et al., 2013). The M-1168 
SHIME model has also been shown to preserve disease signatures, as illustrated by a reduced 1169 
luminal and mucosal Clostridium cluster XIVa colonisation in colon vessels inoculated with 1170 
the faecal material of ulcerative colitis patients compared to healthy donors (Vermeiren et al., 1171 
2012). The mucin-beads technology has recently been transferred into the Artificial Colon 1172 
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(ARCOL), with adaptations to avoid flushing the bioreactor with nitrogen when mucin-coated 1173 
beads are being renewed (Cordonnier et al., 2015, Thevenot et al., 2015) . 1174 
 1175 
Combining colon fermentation models with in vitro cell culture. Recent advancements in the 1176 
field of in vitro fermentation involve the combination of gut microbiota models with a host 1177 
compartment to assess host-microbiota interactions (Bahrami et al., 2011, Marzorati et al., 1178 
2014, Defois et al., 2018). The three-way interactions between host, microbiome and dietary 1179 
interventions can be examined by applying the supernatants of colonic samples onto human 1180 
cell lines or combinations thereof, such as co-cultures of enterocytes and immune cells, in 1181 
Transwell systems (Marzorati et al., 2014). Cytokine and TNF-α production are followed up 1182 
as markers of intestinal inflammation, whereas the trans-epithelial electrical resistance 1183 
(TEER) and Lucifer yellow translocation give an indication of epithelial barrier function 1184 
(Geirnaert et al., 2017). While typically, in human cell line experiments, the short-term effects 1185 
of a single treatment application onto differentiated cells with a disrupted barrier are being 1186 
evaluated, recently, a method was developed to test the effects of a probiotic treatment on the 1187 
development of epithelial barrier integrity during cell differentiation, which is more 1188 
representative of the in vivo situation (Geirnaert et al., 2017). In order to further improve the 1189 
in vivo relevance, a host module, such as the Host Microbiota Interaction (HMI) Module 1190 
(Marzorati et al., 2014), can be coupled to the colonic in vitro fermentation systems described 1191 
above to directly and continuously recirculate the colonic microbial suspension over a mucus 1192 
layer that is in indirect contact with enterocytes and/or immune cells.  1193 
 1194 
4.5. In vivo animal models  1195 
 1196 
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As described above, in vitro mucin-secreting cell cultures, ex-vivo organ cultures as 1197 
well as in vitro fermentation models have yielded fundamental insights into the role of mucins 1198 
and mucus in bacterial interactions with the host. However, the use of in vivo models is 1199 
necessary to study the biological roles of mucins under physiological or pathological 1200 
conditions at the level of entire organism. Genetically modified mouse models with an 1201 
impaired mucin production or glycosylation have been developed to assess the role of mucus 1202 
in the interaction between gut bacteria and the host in vivo.  1203 
  1204 
Muc2-/- mouse model. Many in vivo animal studies investigating the role of mucus in gut 1205 
homeostasis have relied on the use of Muc2-/- mice, lacking the major intestinal mucin Muc2.  1206 
The first studies based on Muc2-/- mice showed that these animals displayed an impaired 1207 
epithelial barrier function characterised by aberrant intestinal crypt morphology and altered 1208 
cell maturation and migration, and that the mice frequently developed adenomas in the small 1209 
intestine, as well as rectal tumours (Velcich et al., 2002). The microscopic analysis of the 1210 
colon indicated mucosal thickening, increased proliferation and superficial erosions (Van der 1211 
Sluis et al., 2006). The development of spontaneous colitis in Muc2 deficient mice indicated 1212 
that Muc2 is critical for colonic protection (Van der Sluis et al., 2006). A gut microbiota 1213 
dysbiosis was also observed in the Muc2-/- mice which harbored a pro-inflammatory-like 1214 
microbiota profile, characterized by an increase in Clostridiales and a decrease in 1215 
Lactobacillaceae (Huang et al., 2015). Furthermore, it was shown that the spatial 1216 
compartmentalization of bacteria in the intestine of Muc2-/- mice was compromised and 1217 
transcriptomic analysis revealed a downregulation of TLR, immune and chemokine signaling 1218 
pathways compared to wild type mice (Sovran et al., 2015) Also, the expression of the 1219 
network of IL-22-regulated defense genes was increased in Muc2-/- mice (Sovran et al., 2015). 1220 
Recent work also confirmed a clear shift in the microbiota composition of Muc2-/- mice, with 1221 
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the Firmicutes phylum enriched and the Bacteroidetes phylum decreased, as well as an 1222 
increase in genera considered as potential pathogens also (Wu et al., 2018). 1223 
Muc2-/- mice have been used to test the effect of the probiotic mixture VSL#3 on 1224 
colonic inflammation and intestinal barrier function (Kumar et al., 2017). This probiotic 1225 
mixture contains eight strains belonging to Lactobacillus, Bifidobacterium and Streptococcus 1226 
genera which are usually found in the human intestinal microbiota. In Muc2-/- mice, VSL#3 1227 
reduced basal colonic proinflammatory cytokine levels and improved epithelial barrier 1228 
function. In addition, VSL#3 reduced the level of proinflammatory chemokines and 1229 
upregulated tissue regeneration growth factors leading to a faster resolution of colitis 1230 
symptoms in Muc2-/- mice with DSS-induced colitis. This was associated with the restoration 1231 
of antimicrobial peptide gene expression in the small intestine, and an increased abundance of 1232 
commensal bacteria in the gut. The authors proposed that these beneficial effects were 1233 
mediated by acetate, produced by the gut bacteria (Kumar et al., 2017). Treatment of Muc2-/- 1234 
mice with Lactobacillus spp. could ameliorate spontaneous colitis and led to an increased 1235 
production of SCFA (Morampudi et al., 2016). 1236 
Muc2-/- mice have also been used to investigate the role of this mucin to prevent 1237 
bacterial and parasite infection. Upon infection with C. rodentium, a murine pathogen related 1238 
to diarrhoeagenic attaching-effacing E. coli, Muc2-/- mice exhibited a rapid weight loss and up 1239 
to 90% mortality (Bergstrom et al., 2010). Mucin secretion was increased in wild type mice 1240 
during infection as compared to the uninfected controls, suggesting that mucin production is 1241 
critical to clear the mucosal surface from pathogenic bacteria. In Muc2-/- mice, commensal 1242 
bacteria were also found to interact with C. rodentium and host tissues, indicating that Muc2 1243 
regulates all forms of intestinal microbiota at the gut surface (Bergstrom et al., 2010). When 1244 
Muc2-/- mice were infected with Salmonella, they showed a dramatic susceptibility to 1245 
infection, carrying significantly higher caecal and liver pathogen burdens, and developing 1246 
 53 
significantly higher barrier disruption and higher mortality rates than wild type mice 1247 
(Zarepour et al., 2013). Colonisation of Muc2-/- mice by enterotoxigenic B. fragilis, a 1248 
causative agent of acute diarrhoea in humans, led to lethal disease (Hecht et al., 2017). The 1249 
protective function of Muc2 was also demonstrated in models of T. muris parasitic infection 1250 
(Hasnain et al., 2010). T. muris is a murine infecting nematode which is used as model of T. 1251 
trichiura infection in humans, a threat in developing countries. After infection, Muc2-/- mice 1252 
showed a delayed expulsion of the worms from the intestine compared to wild type mice. In 1253 
addition, an increase in Muc2 production, observed exclusively in resistant mice, correlated 1254 
with worm expulsion. The nematodes demonstrated a decrease in their energy status in wild 1255 
type mice compared to the susceptible Muc2−/− mice (Hasnain et al., 2010). E. histolytica is a 1256 
human parasite infecting the colon and responsible of amoebic dysentery and/or liver 1257 
abscesses. E. histolytica specifically colonises the mucus layer by adhering to galactose and 1258 
GalNAc residues present in Muc2 (Kissoon-Singh et al., 2013). The parasite also induces 1259 
potent hypersecretion from goblet cells. Kissoon-Singh and colleagues showed that E. 1260 
histolytica induced a pronounced time-dependent secretory exudate with increased gross 1261 
pathology scores and serum albumin leakage in Muc2-/- mice. Colonic pathology, secretory 1262 
responses, and increased pro-inflammatory cytokine secretions were also correlated with 1263 
altered expression of tight junction proteins (Kissoon-Singh et al., 2013). These results 1264 
demonstrate that colonic mucins confer both luminal and epithelial barrier functions and that, 1265 
in the absence of Muc2, mice are more susceptible to E. histolytica-induced secretory and 1266 
pro-inflammatory responses. A recent study using antibiotic treated Muc2-/- and Muc2+/+ 1267 
littermates showed that E. histolytica elicited robust mucus and water secretions, enhanced 1268 
pro-inflammatory cytokines and chemokine expression and higher pathology scores as 1269 
compared to the modest response observed in non-antibiotic treated littermates. Host 1270 
responses were microbiota specific as mucus secretion and pro-inflammatory responses were 1271 
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attenuated following homologous faecal microbial transplants in antibiotic-treated Muc2+/+ 1272 
quantified by secretion of 3H-glucosamine newly synthesized mucin, Muc2 mucin 1273 
immunostaining and immunohistochemistry (Leon-Coria et al., 2018). The mechanism 1274 
controlling mucus release in the presence of E. histolytica was further studied by Cornick and 1275 
colleagues who identified vesicle-associated membrane protein 8 (VAMP8) present on mucin 1276 
granules as orchestrating regulated exocytosis in human goblet cells in response to the 1277 
presence of E. histolytica (Cornick et al., 2017). In Vamp8-/- mice, E. histolytica induced 1278 
enhanced killing of epithelial cells and aggressive proinflammatory response with elevated 1279 
levels of IL-1α, IL-1ȕ, and TNF-α secretion, highlighting the downstream consequences of 1280 
improper mucin secretion in mucosal barrier defence. Taken together, these results 1281 
demonstrate the critical involvement of Muc2 in host protection from nematode infection, by 1282 
constituting an effective physical and biological barrier against pathogenic infection. 1283 
 1284 
Muc1-/- mouse model. Mice impaired in the production of cell surface mucins have also been 1285 
engineered. The Muc1-/- mouse model revealed the role played by Muc1 in H. pylori 1286 
infection, a pathogen involved in gastric ulcers and adenocarcinoma (McGuckin et al., 2007, 1287 
Linden et al., 2009). Muc1-/- mice displayed a 5-fold increase in H. pylori colonisation as 1288 
compared to wild type mice (McGuckin et al., 2007). This study further demonstrated the 1289 
ability of H. pylori to bind to purified Muc1 in vitro, suggesting that Muc1 limits the access of 1290 
H. pylori to the epithelial surface thereby providing protection from infection and 1291 
proinflammatory bacterial products. Muc1 deficiency also resulted in increased epithelial cell 1292 
apoptosis in H. pylori infected mice (Linden et al., 2009). More recently, the long-term 1293 
consequence of Muc1 deficiency on H. pylori pathogenesis was investigated in Muc1-/- mice 1294 
(Ng et al., 2016). Muc1-/- mice began to die 6 months after H. pylori challenge, indicating that 1295 
a deficiency in Muc1 leads to lethal infection. This study also revealed that Muc1 was an 1296 
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important, previously unidentified negative regulator of the NLRP3 inflammasome, and loss 1297 
of this regulation resulted in the development of severe pathology (Ng et al., 2016). 1298 
Consistent with these studies, Muc1-/- mice have a higher rate of systemic infection in a 1299 
murine C. jejuni model of gastroenteritis (McAuley et al., 2007). 1300 
 1301 
Muc13-/- mouse model. The MUC13 transmembrane mucin is highly and constitutively 1302 
expressed in the small and large intestines and MUC13 polymorphisms have been associated 1303 
with human IBD and susceptibility to E. coli infection in pigs. While Muc13-deficient mice 1304 
did not show intestinal pathology, they developed more severe acute colitis than wild type 1305 
mice after DSS challenge, as reflected by increased weight loss, rectal bleeding, diarrhoea and 1306 
histological colitis scores (Sheng et al., 2011). 1307 
 1308 
Mouse models with an altered mucin glycosylation. Loss of O-glycans impairs the 1309 
expression and function of several intestinal mucins, thereafter causing more profound defects 1310 
in the function of the intestinal barrier than a flaw caused by the deficiency of an individual 1311 
mucin. A number of transgenic mouse models have been developed to decipher the 1312 
mechanisms underpinning the role of mucin glycosylation in gut homeostasis. Mice lacking 1313 
core 3–derived O-glycans (also known as C3GnT-/- mice) display a substantial reduction of 1314 
Muc2 protein and an increased susceptibility to DSS-induced colitis and accelerated 1315 
colorectal tumorigenesis (An et al., 2007). In addition, core 3 O-glycosylation was shown to 1316 
play a major role in controlling Salmonella intestinal burdens in C3GnT-/- mice (Zarepour et 1317 
al., 2013). Similarly, C2GnT2-/- mice (mice lacking core 2-derived O-glycans) displayed an 1318 
increased susceptibility to DSS-induced colitis but with no change in Muc2 expression (Stone 1319 
et al., 2009). Mice with intestinal epithelial cell–specific deficiency of core 1–derived O-1320 
glycans (IEC C1galt1-/-) develop spontaneous colitis (Fu et al., 2011). Mice lacking both core 1321 
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1- and core 3–derived O-glycans (DKO mice) have an impaired mucus barrier function and 1322 
develop colitis-associated colon cancer in which the dysbiotic microbiota promote 1323 
inflammation and cancer (Bergstrom et al., 2016). In a water avoidance model in rats, 1324 
psychological stress lead to less-protective mucus layer. In particular, O-glycosylation of 1325 
mucins was strongly affected and these changes were associated with flattening and loss of 1326 
the mucus layer cohesive properties (Da Silva et al., 2014). Altogether, these data suggest that 1327 
the lack of a proper O-glycosylation impairs Muc2 expression or secretion and alters gut 1328 
barrier function of the mucus layer.  1329 
In addition to modifications of mucin core glycans, mouse models have been 1330 
developed targeting epitope modifications of the mucin glycans chains. Dawson and 1331 
colleagues reported that deletion of the sulfate transporter NaS1 in mice (Nas1-/- mice) 1332 
resulting in a decrease in mucin sulfation, enhanced susceptibility to experimental DSS colitis 1333 
and systemic infection by C. jejuni (Dawson et al., 2009). In addition, mice with a deletion of 1334 
the sulfo-transferase GlcNAc6ST2 enzyme adding sulfate to GlcNAC residues on O-mucin 1335 
glycan chains exhibited an increased susceptibility to DSS-induced colitis (Tobisawa et al., 1336 
2010). Mice deleted for Sat-1 (sulphate anion transporter-1) were more susceptible to chronic 1337 
infection by parasite T. muris (Hasnain et al., 2017). Collectively, these findings indicate that 1338 
mucin abnormalities can initiate the onset of inflammatory related diseases in the gut. 1339 
 In addition to mice harbouring a deletion in genes encoding proteins directly involved 1340 
in mucin expression or glycosylation, several transgenic mouse models have been shown to 1341 
display alterations in mucus properties. These include the Winnie and Eeyore mice which 1342 
carry single missense mutations in two different D-domains of Muc2 (Heazlewood et al., 1343 
2008). These mice display fewer goblet cells and a reduction in secreted mucus with O-1344 
glycosylated and non-O-glycosylated Muc2. The misfolding results in endoplasmic reticulum 1345 
stress, goblet cell apoptosis, depletion of the secreted mucus layer and development of 1346 
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chronic intestinal inflammation (Heazlewood et al., 2008). In combination with mucus, a 1347 
large population of intraepithelial lymphocytes (IELs) bearing the Ȗδ T cell receptor is 1348 
mediating immune protection against invading bacteria. In Ȗδ T-cell-deficient (TCRδ−/−) mice, 1349 
mucin expression and glycosylation is altered, mucus-secreting goblet cells are significantly 1350 
reduced in number and those animals are more prone to DSS-induced colitis (Kober et al., 1351 
2014). Mouse models deficient in TLR5, IL-10 and Sodium hydrogen antiporter 3 (Slc9a3 or 1352 
Nhe3) revealed bacteria in contact with the epithelium. Additional analysis of the less 1353 
inflamed IL-10-/- mice revealed a thicker mucus layer but a more penetrable inner mucus 1354 
allowing bacteria to penetrate and reach the epithelium (Johansson et al., 2014).  1355 
 1356 
Non-rodent models. Differences in mucus thickness and composition have been observed 1357 
between rats, pigs and rabbits, and suggests that the pig mucus pattern resembles more closely 1358 
that of humans (Varum et al., 2012). The zebrafish larva is an emerging model system for 1359 
investigating components of the innate immune system, including mucus physiology. It has 1360 
been shown that five gel-forming secreted mucin genes are found in zebrafish with a high 1361 
degree of homology to other vertebrate mucins regarding their genomic and protein domain 1362 
organisation, as well as their tissue specific expression (Jevtov et al., 2014). 1363 
 1364 
5. Limitations of current experimental models involving mucus and future challenges  1365 
 1366 
Given the importance of the gut microbiota as a modulator of health and disease, 1367 
increasing attention has been devoted to the role played by mucus in the interaction with gut 1368 
bacteria (Juge, 2019). As described above (section 4), various experimental models increasing 1369 
in complexity from simple in vitro assays to cell lines, organ-on-chips, in vitro colon 1370 
fermentation systems or animal models have been developed and successfully applied to the 1371 
 58 
study of gut microbe-mucus interactions. However, one of the limitations common to most in 1372 
vitro models is the origin of mucins used to assess the interactions with bacteria doubled by 1373 
the inability to reproduce a colonic mucus gel recapitulating the in vivo situation. This is 1374 
important as the nature and origin of purified mucins used in these assays greatly influence 1375 
the outcome of binding as demonstrated using microtitre plate (Owen et al., 2017), dot-blot 1376 
(Ringot-Destrez et al., 2018) or mucin microarrays (Clyne et al., 2017). Mucin glycosylation 1377 
plays a critical role in the interaction between gut bacteria and mucus and significant 1378 
glycosylation differences occur between purified mucins used in in vitro assays from different 1379 
sites of the murine GI tract or from goblet cells (e.g. LS174T), as analysed by mass 1380 
spectrometry (Leclaire et al., 2018, Ringot-Destrez et al., 2018). In addition, the purification 1381 
steps alter the properties of native glycoproteins and purified mucins used in these assays lack 1382 
the ability to form viscoelastic hydrogels (Kocevar-Nared et al., 1997). A similar situation 1383 
occurs with mucus secreting cell lines where the type of mucins and structure of mucus differ 1384 
from the colonic environment. For example, the HT29 cell line secretes mostly MUC5AC 1385 
whereas MUC2 is the main mucin secreted in the small and large intestines. These differences 1386 
are due to the use of cancer cells which show an alteration in the expression and glycosylation 1387 
of mucins. In addition, the production of mucus by epithelial cell lines can be influenced by 1388 
culture conditions. For example, growing cells on Transwell filters with a small amount of 1389 
apical medium (semi-wet interface culture) in combination with mechanical stimulation (on a 1390 
rocking platform) and addition of the Notch Ȗ-secretase inhibitor DAPT resulted in 1391 
polarisation and secretion of MUC2 and MUC5AC by HT29 MTX-P8, HT29 MTX-E12 and 1392 
LS513 cells (Navabi et al., 2013). Additionally, the mucus produced by goblet cells in in vitro 1393 
co-culture cell models is not continuous nor homogenate which is not fully representative of 1394 
the in vivo situation. Lastly, the formation of the bi-layered mucus found in the colon remains 1395 
a challenge in these models. Novel strategies such as multiple cell layers, 2D-organoid 1396 
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techniques or Organ-on-a-Chip devices are currently being developed to better mimic the 1397 
human intestinal epithelial microenvironment. Such multiple cell models exhibit intestinal 1398 
villus morphogenesis associated with mucus production. These models are also needed to 1399 
recapitulate antimicrobial defense and inflammatory reactions normally occurring in mucosal 1400 
tissues. Another advantage of these systems is that, unlike cell lines, organoids can be used to 1401 
evaluate long-term interactions between mucus and gut microbes. However, these more 1402 
advanced biopsy- based models remain low throughput and expensive as compared to in vitro 1403 
assays and are limited by the availability and variability of clinical specimens. 1404 
In addition, to the host side, several microbial factors must be taken into consideration 1405 
when assaying the interactions between the gut bacteria and mucus. These include the 1406 
handling and labelling microbial cells which may affect the surface molecular determinants 1407 
potentially involved in mucus/mucin interactions (e.g. cell-surface adhesins, pili or flagella) 1408 
(Chagnot et al., 2014). The growth conditions (e.g. growth media with different nutrient 1409 
compositions; temperature, pH, osmolarity or redox potential) can also influence the 1410 
expression of the bacterial receptors mediating the interactions with mucins. To date, most 1411 
studies have focused on the interactions between mucus and probiotic or pathogenic strains 1412 
and assessing strictly anaerobe gut symbionts or complex microbial communities remain a 1413 
challenge in this field of research.  1414 
An alternative to the systems described above is the use of dynamic in vitro 1415 
fermentation models of the human gut, such as the M-SHIME (Marzorati et al., 2014) or DP-1416 
M-SHIME (De Paepe et al., 2018) models. In these in vitro colonic models, the introduction 1417 
of mucin-covered beads allows to study the long-term in vitro microbial colonisation of 1418 
mucin, in the presence of a complex anaerobic intestinal microbiota (Marzorati et al., 2014, 1419 
Shah et al., 2016). These models provide a mean to study gut microbiota functionality and 1420 
niche differentiation, during treatments with xenobiotics (for example antibiotics, synthetic 1421 
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chemicals such as food additives, environmental pollutants like persistent organic pollutants 1422 
(POPs)), pathogens or functional foods. Future developments in this field will be the 1423 
introduction of mucus secretion and/or a mucus surface layer in dynamic in vitro models of 1424 
the upper GI tract, such as in the gastric and small intestinal TNO Gastro-Intestinal model 1425 
(TIM) (Guerra et al., 2012). This is important so to take into account the successive stressful 1426 
events (e.g. acidic gastric pH, bile salts) that commensal or pathogenic microbes undergo in 1427 
the human GI tract before reaching the intestinal epithelium and that may greatly influence 1428 
their physiological stage, virulence and/or activity. 1429 
 However, as mentioned above, a limitation of these in vitro GI models is that they rely 1430 
on commercially available mucins used for the mucin bead technology. These secretory 1431 
mucins, usually MUC5AC and MUC6 porcine gut gastric mucin, differ in terms of structure 1432 
and glycosylation from intestinal MUC2 and cannot form a bi-layered mucus gel. It has been 1433 
proposed that in the future, in vitro engineered mucus may be used to mimic human-derived 1434 
mucus in a more reproducible manner. The colonic in vitro models could also be improved by 1435 
including immunoglobulins, specific antimicrobial peptides, or secreted phosphatidylcholine, 1436 
which have been shown to modulate mucus surface properties, thereby influencing bacterial 1437 
adhesion (Martens et al., 2018). Future in vitro colon models should also better mimic the in 1438 
vivo transit, and particularly retrograde movements (Hiroz et al., 2009), as back-flow was 1439 
recently suggested to be crucial for the persistence of gut microbes in the GI tract (Cremer et 1440 
al., 2016). Current technological advances include the coupling of these fermentation models 1441 
to intestinal epithelial cells or more complex units such as the HMI module. A next step will 1442 
be to couple the digestive/fermentation models with enteroids/colonoids or HIO. However, 1443 
despite their increased complexity, most of these approaches remain limited by the absence of 1444 
important host functions, such as variable peristalsis-like motions. This is a critical limitation 1445 
because mechanical deformations resulting from peristalsis both influence normal epithelial 1446 
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cell differentiation and control microbial overgrowth in the living intestine (Gayer & Basson, 1447 
2009, Benam et al., 2015). The development of microfluidic systems and organ-on-chips is 1448 
currently addressing this important technological gap (Kim & Ingber, 2013, Kim et al., 2016).  1449 
The development of these advanced in vitro systems is essential to help reduce 1450 
dependence on animal studies. Due to the invasive nature of the experiments, the mechanisms 1451 
underpinning microbe-mucus interactions in vivo have mainly been investigated in animal 1452 
models, mostly rodents. Genetically engineered mice impaired in mucin secretion or 1453 
glycosylation have been instrumental to decipher the role of mucins and mucus in the 1454 
protection of the intestinal epithelium and the interactions between pathogenic bacteria, 1455 
commensal microbiota and the mucus barrier. However, although the domain organisation 1456 
and expression pattern of mucins appear largely conserved between human and mouse (Joshi 1457 
et al., 2015), mucin glycosylation (Thomsson et al., 2012) and gut microbiota (Nguyen et al., 1458 
2015) differ between these two species. It has been speculated that differences in mucin 1459 
glycosylation between mammalian species may underlie some of the differences in infectivity 1460 
and/or pathogenicity for individual microbial pathogens (Linden et al., 2008) or the different 1461 
commensal microbiota (Thomsson et al., 2012). Therefore, caution should be applied when 1462 
translating data obtained in mouse models to humans. Lastly, unlike in vitro assays, in vivo 1463 
studies are restricted to end-point measurements.  1464 
 Recent years have witnessed unprecedented technological advances in the 1465 
development of in vitro GI models that more closely resemble the gut mucosal interface. Our 1466 
next challenge will be to simulate these models at different stages of development or disease 1467 
conditions (e.g. IBD, obesity or CF). Special attention should be paid to inter-individual 1468 
differences and intra-individual variability in gut microbiota composition and intestinal 1469 
biopsies from different donors or patients. This is important to better understand the role of 1470 
gut microbe-mucus interactions in the aetiology of a particular disease or condition and 1471 
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determine the microbial and biochemical signature that could differentiate between diseased 1472 
or healthy status. In particular, more research is warranted to determine how the 1473 
physicochemical properties and/or thickness of the mucus layer and mucin glycosylation are 1474 
altered during a specific disease. In the future, these pre-clinical models will help screen novel 1475 
therapeutic strategies aimed at restoring gut barrier function and tailored to the individual 1476 
patient as a step towards personalised medicine.   1477 
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 2379 
Types of models Description Applications Advantages Limitations References 
In vitro mucus/mucin binding assays      
Microplates - Flow chambers 
     
 
* Immobilization of 
mucus/mucin on the 
microtiter plate 
* Microtiter plate : 
adhesion in static 
conditions 
* Flow chambers : 
adhesion under dynamic 
conditions (fluid shear) 
 
* Evaluation of bacterial 
adhesion (commensals 
and pathogens) to 
mucins and molecular 
mechanisms associated 
 
* Fast, quantitative and high 
throughput method to study 
mucus-microbe interactions 
independently from other in 
vivo conditions 
* Identification of molecular 
determinants involved in 
adhesion of microbes 
* Coupling with biophysical 
techniques (Surface Plasmon 
Resonance, Atomic Force 
Microscopy) 
* Influence of experimental 
conditions (antibiotics, 
mechanical treatments, growth 
conditions, hydrophobic 
interactions) 
* Limited availability of purified 
mucins (mainly use of pig 
gastric mucin) 
* Absence of gut microbiota 
McNamara et 
al., 2000, 
Gusils et al., 
2004 ; 
Ringot- 
Clyne et 
al.,2017 
Dunne et al. 
2018 
In vitro cell models      
Monoculture models 
     
 
* Gut–derived epithelial 
cells resembling intestinal 
tissue consisting mainly 
of mature goblet cells that 
secrete an adherent  
 
* Adherence of 
commensal and 
pathogenic bacteria to 
host cells  
* Effect of 
commensals/pathogens 
on host cell mucin 
synthesis and/or 
composition of the 
mucus layer 
 
* Reproducible and easily 
handled in laboratories 
* Identification of molecular 
determinants involved in 
adhesion of microbes and 
host cell  mucin synthesis  
* Good platform for 
screening and characterizing 
probiotic activity 
* Derived from cancer cells, 
different from healthy tissue 
* Not representative of various 
cell types recovered in mucosal 
epithelial tissues 
* Not representative of 
appropriate MUC gene 
expression 
* Modulation of mucus 
production by culture conditions  
* Absence of gut microbiota 
* Difficulty to maintain for 
long-term experiments (>1 
month) 
* Requirement of high oxygen 
levels (difficulty to study 
oxygen-sensitive microbes) 
Linden et al., 
2007,  
Navabi et al., 
2013,  
Hews et al., 
2017 
Co-culture models 
     
 
* Mixed culture of 
enterocytes and mucin 
secreting cells 
 
* Adherence of 
commensal and 
pathogenic bacteria to 
host cells  
* Effect of 
commensals/pathogens 
on host cell mucin 
synthesis and / or 
composition of the 
* Better representation of 
cell-type ratio recovered in 
mucosal epithelial tissues 
* Simple model, well 
described in literature 
 
* Absence of M-cells 
(development of triple co-culture 
Caco-2/HT29-MTX/Raji B)  
* Variations in seeding ratios of 
HT29 MTX/Caco-2 can impede 
results interpretation 
* Modulation of mucus 
production by culture conditions  
* Absence of gut microbiota 
* Difficulty to maintain for 
Hilgendorf et 
al., 2000, 
Lozoya-
Agullo et al., 
2017 
mucus layer 
 
long-term experiments (>1 
month) 
* Requirement of high oxygen 
levels (difficulty to study 
oxygen-sensitive microbes) 
  
Ex-vivo organ cultures      
Intestinal organoids 
     
 
* Generation of self-
propagating spheres of 
primary intestinal 
epithelial cells  
* Enteroids = derived 
from adult stem cells 
isolated from the crypts 
of human small intestinal  
* Colonoids =  derived 
from adult stem cells 
isolated from the crypts 
of human colonic tissue 
* Study of advanced 
aspects of mucus 
development in a more 
complex scenario 
* Study of host–
commensals and 
pathogens interactions 
 
* Often collected from mice 
tissues, possible use of 
patient-derived tissues 
* Assay that more accurately 
mimics in vivo conditions 
* Amenable to long-term 
culture 
 
* Highly expensive and requires 
specialized expertise 
* Requires access to 
biopsies/tissues  
* Donor-to-donor variability 
* Requirement of injection to 
infect organoids  with bacteria 
* Absence of gut microbiota 
* No reproduction of peristalsis 
motions and GI stressful events 
* Requirement of high oxygen 
levels (difficulty to study 
oxygen-sensitive microbes) 
Jung et al., 
2011,  
Sato et al., 
2011 
In vitro organ culture (IVOC)     
 
 
* Whole organs 
maintained in vitro 
* Study of host–
commensals and 
pathogens interactions 
* Better maintenance of 
tissue architecture  
* Presence of non-
transformed cells including 
all major cell types 
(enterocytes, goblet cells, 
Paneth cells and endocrine 
cells) 
* Often collected from 
animal tissues, possible use 
of patient-derived tissues 
* Possible use of biopsies 
from disease patients (e.g. 
IBD) 
* Requires access to 
biopsies/tissues  
* Expensive and requires 
expertise 
* Donor-to-donor variability 
* Difficulty to maintain for 
long-term experiments 
* No reproduction of peristalsis 
motions and GI stressful events 
* Requirement of high oxygen 
levels (difficulty to study 
oxygen-sensitive microbes) 
 
Browning & 
Trier, 1969, 
Schüller et 
al., 2007 
Gut- on-a chip     
 
 
* Reproduction of the 
multicellular structures, 
cell–cell and tissue–tissue 
interactions, and the 
native microenvironment 
* Closely reproduction of 
the in vivo situation 
* Study of the complex 
physiological and 
pathophysiological 
responses of tissues at 
an organ level 
* Study of host–
commensals and 
pathogens interactions 
 
* Presence of non-
transformed cells including 
all major cell types 
(enterocytes, goblet cells, 
Paneth cells and endocrine 
cells) 
* Reproduction of peristalsis 
like motions  
* Possible use of biopsies 
from disease patients (e.g. 
IBD) 
* Expensive and requires 
dedicated expertise and 
instrumentation 
* Stem cell differentiation is 
difficult to achieve 
* Flow rate of the medium can 
influence cell metabolism 
* Absence of gut microbiota 
* No input from  immune and 
nervous system 
* Requirement of high oxygen 
levels (difficulty to study 
oxygen-sensitive microbes) 
* No reproduction of the full 
Kasendra et 
al., 2018 
 
complexity of the human gut 
microbiota 
 
In vitro human colonic models 
involving a mucosal phase 
     
M-SHIME 
     
 
* Series of bioreactor 
modeling the different 
parts of the human gut 
* Introduction of mucus-
coated carriers (Mucus 
SHIME) 
* Study the fine-scale 
spatial organization of 
the gut microbial 
ecosystem 
* Investigation of the 
interactions between 
commensals, pathogens, 
probiotics and 
luminal/mucosal gut 
microbiota  
 
* Integration of human GI -
related parameters and 
possibility to modulate them 
depending on diet, age and 
diseases (e.g. ulcerative 
colitis) 
* Capture dynamics by time-
resolved analyses 
* Capture inter-individual 
variability of human gut 
microbiota 
* Possible long term 
experiments 
* Possible coupling with cell 
culture models and Host-
Microbe Interactions (HMI) 
module  
* Expensive and requires 
expertise and specialized 
instrumentation 
* Use of pig gastric mucin 
* No reproduction of immune 
and nervous system 
* No reproduction of the full 
complexity of the human gut 
microbiota 
* Donor-to-donor variability 
 
Van den 
Abbeele et 
al., 2012 
Van den 
Abbeele et 
al., 2013 
De Paepe et 
al., 2018 
In vivo animal models      
 
* Whole organism 
models 
* Development of 
genetically modified mice 
with impaired mucin 
production (comparison 
with wild type animals) 
* Study of the functional 
roles of mucin and 
mucus under 
physiological or 
pathological conditions 
at the level of entire 
organism 
* Investigation of 
downstream 
consequences of mucin 
modulation in mucosal 
barrier defense 
* Investigation of the 
interactions between 
commensals, pathogens, 
probiotics and 
luminal/mucosal gut 
microbiota  
* Physiological model 
* Allow targeting of a 
specific gene/pathway in the 
complex gut-microbiota – 
host interactions  
* Amenable to diet or 
microbiome-based 
interventions 
* Possible long-term 
experiments 
 
* Requires housing facility and 
adequate agreements 
* Expensive to maintain 
colonies 
*Housing husbandries and diets 
can modulate mouse microbiota 
* Murine gut microbiota 
different from the human gut 
microbiota 
* Mucin glycosylation profile of 
mice different from human 
intestinal mucins 
* No reproduction of the full 
complexity of the human gut 
microbiota 
* Limited translational capacity 
to human situation 
* Mice generally inbred so no 
reproduction of the genetic 
variations found in the human 
population 
Van der Sluis 
et al., 2006 
Velcich et 
al., 2002 
 
Table 1. Experimental models available to study mucus-bacteria interactions. 
GI : Gastro-Intestinal, HMI : Host-Microbe Interactions, IBD : Inflammatory Bowel Ddiseases, 
IVOC : In vitro organ culture, M-SHIME : Mucus Simulator of the Human Intestinal Microbial 
Ecosystem. 
 


FIGURE LEGENDS 
Fig. 1. Mucin-bacterial interactions in the digestive tract 
Left panel: Mucins display various and diverse oligosaccharide structures representing 
potential binding sites for microbial adhesion. Commensal and pathogenic microbes can use 
cell-surface appendages, such as pili, flagella or fimbriae or adhesins to bind to mucus. 
Right panel: Mucin glycans are an important energy source for microbes inhabiting the mucus 
niche that further confer them with an ecological advantage over other members of the gut 
microbiota. Commensal and pathogenic microorganisms can degrade mucin glycan chains 
leading to the release of mono- or oligosaccharides from that can be subsequently metabolized 
by other gut microbes in the mucosal environment.  
 
Fig.2. Perturbations of the mucus barrier in response to environmental and microbial 
stimuli. 
This figure represents an overview of the various factors (diets, nanomaterials, pollutants, 
antibiotics or invading pathogens) affecting the gut microbiota composition and/or the 
thickness, structure and composition of the mucus barrier. Disruption of the mucus layer 
promotes bacterial encroachment leading to the subsequent development of low-grade 
inflammation, associated with inflammatory bowel diseases and metabolic disorders. 
 
